分类： ACN Newswire

Novelty and inventiveness confirmed as Focus Graphite moves closer to securing patent for next-generation lithium-ion battery anode materialsOttawa, Ontario--(ACN Newswire via SeaPRwire.com - August 20, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") is pleased to provide an update on the status of its patent application entitled "Advanced Anode Materials Comprising Spheroidal Additive-Enhanced Graphite Particles and Process for Making Same" (Canadian patent application No. 3,209,696).The Company reports that no further prior art has been cited in the examination process. The remaining requests for clarification from the examiner are minor in nature, primarily relating to formality issues in the description and figures. Focus is pleased with this outcome and has retained MBM Intellectual Property Law ("MBM") of Ottawa, ON, to prepare and submit claim amendments and expects a positive resolution.In support of its application, Focus has also received the International Preliminary Report on Patentability ("IPRP") issued during the Patent Cooperation Treaty ("PCT"). The IPRP confirmed that the Company's amended claims are both novel and inventive, strengthening the intellectual property protection around Focus' proprietary anode material technology.Additionally, the Company submitted amended claims under the Patent Prosecution Highway ("PPH") for the Canadian case. These amendments, which reduced the number of claims to avoid excess fees, form the basis for the Company's ongoing patent strategy.Dean Hanisch, Chief Executive Officer of Focus Graphite, commented, "This positive progress in our patent application process represents another important milestone in advancing Focus Graphite's downstream strategy. The recognition that our claims are both novel and inventive underscore the uniqueness of our technology and its potential to contribute meaningfully to next-generation lithium-ion battery anode materials."The Company will provide further updates as the application advances.About MBM Intellectual Property LawMBM is an independent, Canadian-owned boutique law firm dedicated exclusively to intellectual property law headquartered in Ottawa. For over 30 years, MBM has provided strategic IP advice and protection for clients ranging from start-ups and universities to multinational corporations. With a diverse team of patent and trademark agents, lawyers, and scientists, MBM manages global patent, trademark, and design portfolios and is recognized for delivering practical, cost-effective solutions. Proudly independent, MBM focuses on building long-term client relationships and maximizing the value of innovation.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the anticipated outcome of Focus Graphite's patent application process; the Company's ability to address and resolve the examiner's remaining objections; the expectation of securing patent protection for spheroidal additive-enhanced graphite materials; the potential strategic, commercial, and technological benefits of securing such intellectual property; and the advancement of the Company's downstream strategy to supply advanced graphite materials for lithium-ion batteries in North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263193 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

A bubbly boost to Malaysians’ favourite drinks, uniting the nation through flavour and funKUALA LUMPUR, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - This Merdeka and Hari Malaysia, Spritzer Sparkling is adding an extra pop to the nation’s celebrations with “Kasi Sparkling, Baru Kick!”. This high-energy campaign is a tribute to Malaysia’s favourite pastime – bonding over hearty food and thirst-quenching drinks. From the eternal “Where to eat?” debates to late-night mamak sessions that stretch into early mornings, these shared moments are part of what makes us Malaysian.Inspired by the lively, welcoming atmosphere of mamak restaurants nationwide – the melting pot where Malaysians of every race, language, and background gather – Spritzer Sparkling is bringing a fun twist to your favourite local beverages with exciting engagement games and prizes to be won at selected mamak outlets, guaranteed to refresh your senses and spark national pride.Mamak Culture, Now with More SparkleFrom teh ‘o’ to sirap limau and asam boi, Malaysian drinks are iconic in their own right. Spritzer Sparkling is taking these familiar flavours and giving them a bubbly boost at some of your favourite neighbourhood mamak restaurants, creating new taste experiences that blend tradition with modern fun.Mamak restaurants have always been the heart of get-togethers for Malaysians from all walks of life; where friends, families, and even strangers share tables, stories, and laughter. This campaign captures that same magic in every sip, celebrating the diversity of our people while proving that great taste knows no boundaries.Photo 1: The three new Spritzer Sparkling drink recipes in the Kasi Sparkling, Baru Kick! CampaignA Campaign Video That is Bursting with EnergyShowcasing the Malaysian spirit, “Kasi Sparkling, Baru Kick!” is a colourful, feel-good celebration video featuring “Aneh”, the friendly mamak waiter. Infused with a twist on our favourite thirst-quenchers, the campaign highlights three mouth-watering drink recipes, each given an irresistible sparkling twist, brought to life by a vibrant local cast speaking different regional dialects, with Aneh delivering the mamak’s urban rhythm in his signature rap style.Watch it now on Spritzer Water YouTube channel and feel the fizz yourself.Photo 2: Kasi Sparkling, Baru Kick! campaign videoJoin the Festivities NationwideFrom Merdeka to Malaysia Day, the celebration will come alive with a sparkling kick at selected mamak chain outlets – including Restoran Nasi Kandar Subaidah, Restoran Hameediyah, and Nasi Kandar Bestari. Enjoy exclusive combo deals featuring the new sparkling drink creations and join exciting roving roadshows designed to surprise, delight, and refresh your taste buds.Whether you are there for the food, the drinks, or the atmosphere, you will not want to miss this limited-time celebration. All event details, locations, and recipes are available at the official campaign page: sparklingmerdeka2025.spritzer.com.mySo, this season, let us raise our glasses to unity, flavour and fizz. Your favourite local drinks are getting a sparkling new twist—Malaysian flavours with extra kick—ready to enjoy at home or at your favourite mamak. Taste the celebration, anywhere you are.About SpritzerEstablished in 1989, Spritzer is Malaysia’s largest producer of bottled water, offering a wide range of products that include natural mineral water, distilled water, sparkling water, carbonated fruit-flavoured drinks, and non-carbonated fruit-flavoured drinks.Our water is sourced from deep underground aquifers within 430 acres of pristine rainforest, naturally protected from pollution. It takes over 15 years to filter through ancient rock layers, becoming enriched with essential minerals, particularly silica, which supports collagen formation for healthy skin and strong bones.Spritzer is committed to sustainability and innovation, using 100% recyclable packaging and working toward becoming a fully circular brand by 2030. Our Industry 4.0 facilities and zero-energy automated warehouse demonstrate our dedication to efficiency, environmental care, and forward-thinking growth.For more information, please visit www.spritzer.com.my.For media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- 朗豪坊商场开业20周年"立足本地，引领全球潮流文化"，成品牌进驻热点，Chiikawa拉面首间海外分店掀热潮- 花园道三号于2025年到期的租约已全部处理，续约率维持在高水平- 朗豪坊办公楼推出结合六大健康维度"6D Wellness"的创新概念，强化其一站式身心健康及生活时尚总汇的市场定位- 香港银行同业拆息下降节省利息开支，2025年债务成功全额再融资香港，2025年8月20日 - (亚太商讯 via SeaPRwire.com) - 持有花园道三号及朗豪坊物业的冠君产业信托（股份代号：2778）公布截至 2025 年 6 月 30 日止的中期业绩。业绩摘要 2025上半年2024上半年变动租金收益总额 （百万港元）1,0291,115- 7.6%物业收益净额（百万港元）859954- 10.0%可分派收入（百万港元）476544- 12.6%  每基金单位分派（港元）0.07010.0809- 13.3% 于2025年6月30日于2024年12月31日变动物业组合总值（百万港元）58,09860,104- 3.3%每基金单位资产净值（港元）6.797.16- 5.2%资产负债比率24.5%23.7%+ 0.8pp概览2025年上半年，尽管全球经济因贸易紧张局势和地缘政治冲突而面对重重阻力，但香港的市场气氛获多项利好因素支持。股市回暖、香港银行同业拆息于第二季回落，住宅销售趋稳定，以及旅游业稳步复苏均有助抗衡外部压力。然而，港人外游热潮未退，消费力外移令本地零售市道受压。与此同时，写字楼租赁市场依然淡静，反映供求持续失衡。在此市况下，本信托的可分派收入下跌12.6%至4.76亿港元，而每基金单位分派（"每基金单位分派"）则减少13.3%至0.0701港元。冠君产业信托行政总裁侯迅女士（左），冠君产业信托投资及投资者关系总监陆嘉萍女士（右）花园道三号虽然中环整体写字楼市场的租赁动力仍然疲弱，但随着金融市场转趋活跃，我们接到的租赁查询有所增加，需求主要来自金融相关企业。花园道三号落实引进一批新的租赁面积较小的租户，包括家族办公室；而一名现有银行业租户亦于物业内扩充。于2025年6月30日，花园道三号写字楼的出租率为80.7%。该物业的租金收益期内减少5.4%至5.40亿港元（2024年：5.71亿港元）。我们持续推动续租工作，2025年到期的租约已全部处理完毕且续约率维持在高水平，当中包括多名主要租户的续租。而2026年到期的租约亦有超过70%已续租。朗豪坊办公楼报告期内，朗豪坊办公楼推出名为"6D Wellness"的YouTube频道，藉此强化朗豪坊办公楼作为一站式身心健康及生活时尚总汇的市场定位。于2025年6月30日，在该物业的租户组合中，生活时尚（身心健康）行业租户占比达68%。于2025年6月30日，朗豪坊办公楼的出租率保持在86.9%的稳定水平。我们扩大了共享工作空间的营运规模并增设"Social Wellness Hall"，专为举办工作坊及交流活动而设，正好呼应办公楼推广身心健康的定位。市场租金继续面对挑战，租金收益因而减少9.1%至1.51亿港元（2024年：1.66亿港元）。冠君产业信托行政总裁侯迅女士朗豪坊商场今年迎接开业20周年的朗豪坊商场，继续秉持"Stay Local，Trend Global"（"立足本地，引领全球潮流文化"）的愿景。透过沉浸式体验和限定商品，我们成功吸引破纪录的人潮及推动销售，并在八月刷新单日人流纪录。近日，首次进军香港的时装品牌BENLAI，以及全城首家以生活风格为主题的期间限定店Umbro均在朗豪坊商场开业，人气拉面店Chiikawa Ramen Buta亦选址朗豪坊商场设立首家海外分店，旋即成为高人气新热点。于2025年6月30日，商场的出租率维持在99.2%的高水平，目前属已承诺悉数租出的状态。消费行为的改变为租户带来挑战，租金收益跌至3.38亿港元（2024年：3.78亿港元）。分派本信托期内可分派收入下跌12.6% 至4.76亿港元（2024年：5.44亿港元），而每基金单位分派则减少13.3%至0.0701港元（2024年：0.0809港元）。按2025年6月30日的基金单位收市价2.08港元计算，相当于年度分派率6.7%。资产值于2025年6月30 日，本信托旗下物业组合的估值为581亿港元，较2024年12月31日的601亿港元减少3.3%。可持续发展我们继续透过提升气候抗御力、建立有意义的联系及促进社区福祉，为我们的生态圈创造共享价值。报告期内，花园道三号引入人工智能制冷机组优化系统，全年节省大厦制冷设备的能源用量达6.1%。我们透过"绿'惜'环保约章"计划，推动写字楼和零售租户携手实现可量化的环保目标。此外，我们举办以"创新．启发．融合"为主题的"冠君产业信托 ESG Gala"，凝聚逾千名租户和商业伙伴，共同推进可持续营运及共融举措。展望尽管香港零售业已重拾增长，金融市场亦见反弹，预料本信托于2025年后续期间的整体经营环境依然严峻。虽然港元利率回落有助节省利息支出，但续租租金下跌或将持续压抑租金收益及令分派较去年为低。面对竞争激烈的市场环境，我们将继续以灵活的营运策略积极应对。有关冠君产业信托(股份代号：2778)冠君产业信托拥有及投资提供租金收入的写字楼及零售物业。信托主要投资位于优越地点的甲级商用物业。现时拥有花园道三号及朗豪坊两幢位于香港的地标性物业，并以合资股权形式拥有位于伦敦市中心的 66 Shoe Lane，总楼面面积约300万平方呎，让投资者可直接投资于优质甲级写字楼及零售物业。信托自2023年荣获全球房地产GRESB可持续的最高五星级别。冠君产业信托管理人乃鹰君资产管理（冠君）有限公司，为鹰君集团的成员。网站:  www.championreit.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Financial Highlights:(RMB Million)For the Six Months Ended 30 June1H 20251H 2024% ChangeRevenue5,8506,007- 2.61%Gross Profit8481,003- 15.45%Profit Before Tax839899-6.67%Net Profit Attributable to Owners of the Company641687- 6.70%Basic Earnings per Share (RMB)0.140.15- 6.67%HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - China BlueChemical Ltd. (“China BlueChem” or the “Company,” stock code: 3983), China’s largest chemical fertilizer central enterprise in both production capacity and production volume, has announced its unaudited interim results for the six months ended 30 June 2025. In the first half of 2025, the Company realized a revenue of RMB 5.85 billion, slightly down by 2.6% year-on-yearly. Net profit attributable to owners of the Company amounted to RMB 641 million, a slight year-on-year decrease of 6.7%.Mr. RAO Shicai, CEO of China BlueChem said, “Despite the complex and volatile external environment and internal structural adjustment pressures, the Company’s key operating indicators have been successfully achieved. During the period, the Company has strengthened its safety production management, actively expanded its market and sales channels, and further developed lean management, while at the same time steadily implementing various measures to stabilize growth, reinforce reforms, and enhance efficiency Moreover, the Company has consistently adhered to a philosophy of green and sustainable development. Its methanol plant has been awarded the honorary title of “Energy Efficiency Leader” by the China Petroleum and Chemical Industry Federation for 14 consecutive years, and its synthetic ammonia plant has been awarded the honorary title of “Water Efficiency Leader” by the China Nitrogen Fertilizer Industry Association for 6 consecutive years. It also won the “2025 ESG Model Enterprise Award” at the 4th International Green Zero-Carbon Festival and ESG Leadership Summit, setting a benchmark for sustainable development brands.”In respect of production management, the Company continuously strengthened production and operation control and system management, thoroughly implementing the concept of green development and stable safety production conditions. During the period, methanol production at CNOOC Fudao and the cumulative throughput at Basuo Port both reached new highs for corresponding periods in history. The CNOOC Huahe Chemical Fertilizer Plant achieved 314 days of continuous operation, making a new record of itself and setting outstanding production indicators. In the first half of the year, the Company produced 968,000 tonnes of urea, 781,000 tonnes of methanol, 450,000 tonnes of phosphate fertilisers and compound fertilizers, and 132,000 tonnes of acrylonitrile series products.With regard to sales management, amidst the complex and ever-changing market situation, the Company has continued to further strengthen market analysis and keep up with the market to implementprecise pricing. By solidifying the weekly production and sales coordination meeting mechanism, the Company has optimised storage and transportation coordination, and ensured efficient product circulation., It has also comprehensively advanced market expansion and efficiency improvements. In the first half of the year, the Company sold 996,000 tonnes of urea, 726,000 tonnes of methanol; 386,000 tonnes of phosphate fertilizers and compound fertilizers, and 127,000 tonnes of acrylonitrile series products.As for green development, the Company accelerated the implementation of key projects, successfully producing the first tonne of green methanol in China using urban waste as raw material, and obtaining International Sustainability and Carbon Certification (ISCC) in the first half of the year. The green methanol has been successfully applied to domestically produced dual-fuel vessels, marking the first domestic use of green methanol. Furthermore, the Company achieved unified integration of monitoring data into the environmental protection information system, with pollutant emissions meeting standards at 100% for three consecutive years, and the number of environmental pollution incidents remaining at zero. The comprehensive utilization rate of phosphogypsum at DYK increased from 61.15% to 73.09%, exceeding the target requirements.Looking ahead to the second half of the year, urea will remain in a capacity expansion cycle and the overall market will continue to be oversupplied. In the third quarter, demand will be stronger driven by the combined impact of the export window and agricultural demand. Entering the fourth quarter, the release of new capacity and weakening demand will create a ripple effect, and prices are expected to remain under pressure. The prices of monoammonium phosphate may fluctuate within a narrow range at a high level, supported by strong raw material costs and favorable demand factors. The diammonium phosphate market is expected to maintain a stable consolidation cycle. In the third quarter, domestic autumn storage and export demand will resonate, resulting in strong overall demand and stable prices. In the fourth quarter, the demand for phosphate fertilizer is expected to decline overall, putting downward pressure on prices, but overall fluctuations will be relatively limited, supported by cost factors. In the second half of the year, the trend of methanol supply is expected to remain accommodative. Benefited from anti-involution in mainland China and the restriction policy on new coal-to-methanol projects, the supply and demand structure is expected to be improved. Downstream demand may see a phased recovery, with the overall market trend characterized by fluctuations. Regarding acrylonitrile, the oversupply situation will further intensify. Any improvement in acrylonitrile prices will require major domestic companies to reduce plant loads.Mr. RAO Shicai, CEO of China BlueChem said, “In the second half of 2025, the Company will refine its equipment management system to ensure safe and stable operation of facilities and establish a solid foundation for intrinsic safety. At the same time, it will focus on establishing its quality positioning, expanding market and sales, and enhancing marketing effectiveness. "AI+" initiatives will be promoted across the Company to accelerate the deep integration of digital technology and the real economy. In addition, the Company will push forward the study of key projects on the utilization of carbon-rich natural gas and strengthen communication matrix management to continuously enhance brand value.”About China BlueChemical Ltd.China BlueChemical Ltd. (“China BlueChem”) is a listed company that specialises in the development, production and sales of chemical fertilisers and synthetic chemical products. It is the largest Central enterprise in the field of chemical fertilisers in terms of both production capacity and production volume. The Company is a subsidiary of China National Offshore Oil Corporation which mainly engages in the exploration, development, production and sales of crude oil and natural gas. On 29 September 2006, China BlueChem was listed on the main board of The Stock Exchange of Hong Kong Limited with the stock code 3983. Currently, its production facilities are located in Hainan, Hubei and Heilongjiang, China, with a total designed annual production capacity of 1.84 million tonnes of urea, 1.3 million tonnes of phosphate and compound fertilisers (mono-ammonium phosphate, di-ammonium phosphate and compound fertiliser), 1.4 million tonnes of methanol, 200 thousand tonnes of acrylonitrile and 70 thousand tonnes MMA. It has a deep water port with a designed annual throughout capacity of 18.28 million tonnes in Dongfang city, Hainan province. Boasting continued growth of its brand value, the Company’s brand value reached historical high at RMB7.258 billion in 2025. Besides, the Company was awarded “ËSG Model Enterprise 2025” at the 4th International Green Zero-Carbon Festival Cum ESG Leaders Conference.For more information about the Company, please visit its website:www.chinabluechem.com.cn. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BRISBANE, AUS, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Cholrem Pty Ltd, an Australian pharmaceutical research company, has published a landmark study in Cardiology Research and Cardiovascular Medicine, revealing that its proprietary cyclodextrin-based therapy Cavadex reverses atherosclerotic cardiovascular disease (ASCVD), the world's leading cause of death.Angiogram: Plaque Reduced Within 6 WeeksThe peer-reviewed case series demonstrates rapid symptom relief and significant regression of arterial plaque, marking a potential paradigm shift in heart disease treatment. The study followed 20 high-risk patients with advanced angina, with 18 (90%) reporting substantial symptom improvement (P0.0001) compared to expected outcomes. Objective imaging confirmed unprecedented results, including Coronary Artery Calcium (CAC) score reductions (e.g., from 591 to 521) and a 70% coronary artery blockage reduced to 27%. Cavadex, formulated with 2-hydroxypropyl-β-cyclodextrin (HPβCD), stimulates the body's natural vascular repair, offering a faster, more effective approach than existing therapies.The late Professor Laurie G. Howes, a renowned Australian cardiologist and study co-author, called Cavadex "the greatest pharmacological development in cardiology since statins." U.S. cardiologist Dr. James C. Roberts, who has treated hundreds with the therapy, noted, "We're seeing rapid, profound improvements in high-risk patients, with objective plaque regression and an excellent safety profile, leveraging a TGA- and FDA-approved molecule."Cholrem, founded by Kyle Hodgetts - a heart disease patient who pioneered Cavadex after conventional treatments failed - has supplied over 20,000 units globally. Despite HPβCD's non-patentable status limiting industry investment, Cholrem is driving this breakthrough forward. The company urges global medical communities to launch large-scale trials to validate these findings for millions suffering from heart disease.About Cholrem Pty Ltd: Cholrem is dedicated to advancing cyclodextrin-based therapies to combat ASCVD, the world's top killer, with a mission to deliver innovative, life-saving treatments. Cardiology Research and Cardiovascular Medicine Published Paper: https://www.gavinpublishers.com/article/view/cyclodextrin-therapy-for-atherosclerotic-cardiovascular-disease-a-case-series-on-plaque-regression-and-symptomatic-improvementRelated Videohttps://www.youtube.com/watch?v=5JqIanZxmuQContact InformationKyle HodgettsCholrem Pty Ltd Founder & CEOinfo@cholrem.com+61 424830574Related Videohttps://www.youtube.com/watch?v=5JqIanZxmuQSOURCE: Cholrem Pty Ltd Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

财务摘要(人民币亿元)截至 6 月 30日止年度2025年中期2024年中期变动收入58.5060.07- 2.61%毛利8.4810.03- 15.45%税前利润8.398.99-6.67%本公司拥有人应占净利润6.416.87- 6.70%每股基本盈利 (人民币元)0.140.15- 6.67%香港，2025年8月19日 - (亚太商讯 via SeaPRwire.com) - 中海石油化学股份有限公司(「中海石油化学」或「公司」，股份编号：3983) 公布截至2025年6月30日止日止半年度未经审计之业绩。2025年上半年公司实现收入人民币5,850百万元，同比微跌2.6%，本公司拥有人权益应占净利润为人民币641百万元，同比微跌6.7%。中海石油化学首席执行官饶仕才先生表示：「纵使面对外部环境复杂多变与内部结构调整压力，公司主要经营指标仍然完成良好。期内，公司继续强化安全生产管理，积极拓展市场与销售渠道，深化精益管理；同时，扎实推进稳增长、深改革、提效能各项工作。此外，公司坚持秉持绿色可持续发展理念，甲醇装置连续十四年获评石化联合会『能效领跑者』荣誉称号，合成氨装置连续六年蝉联氮肥协会『水效领跑者』 荣誉称号，并荣膺第四届国际绿色零碳节暨ESG领袖峰会『2025 ESG 典范企业奖』，树立了可持续发展品牌标杆。」生产管理方面，公司持续强化生产经营管控与体系管理，深入践行绿色发展理念，安全生产形势总体平稳。期内，海南富岛甲醇产量与八所港累计吞吐量均创历史同期新高，华鹤煤化工化肥装置实现314天长周期运行，刷新自身纪录，生产指标表现亮眼。上半年，公司生产尿素96.8万吨、甲醇78.1万吨、磷肥及复合肥45.0万吨、丙烯腈系列产品13.2万吨。销售管理方面，面对复杂多变的市场形势，公司持续深化市场研判，紧贴市场精准定价。通过固化产销协同周例会机制，优化储运衔接，保障产品高效流通。同时加大出口创效力度，全面推进拓市增效。上半年，公司销售尿素99.6万吨、甲醇72.6万吨、磷肥及复合肥38.6万吨、丙烯腈系列产品12.7万吨。绿色发展方面，上半年公司加速推进重点项目落地，成功产出以城市垃圾为原料的国内首吨绿色甲醇，并获得国际可持续发展和碳认证（ISCC）。该产品成功应用于国产双燃料船舶，实现了国内绿色甲醇首次加注。此外，公司实现监测数据统一接入环保资讯系统，污染物排放连续三年100%达标，环保污染事故事件保持为零。其中，大峪口化工磷石膏综合利用率由61.15%提升至73.09%，超额完成指标要求。展望2025下半年，尿素仍处于产能扩张周期，市场整体将延续「供大于求」格局，三季度受出口窗口期与农需支撑迭加影响，需求较强;进入四季度后，新增产能释放与需求转淡形成共振，价格预计持续承压。磷酸一铵价格或呈高位窄幅震荡态势，一方面原料成本支撑强劲，另一方面需求端亦有利好因素加持。磷酸二铵市场预计维持稳中整理节奏，三季度国内秋储与出口需求共振，整体需求旺盛，价格将保持平稳运行;四季度磷肥需求预计整体回落，价格存在回调压力，但受成本端支撑，整体波动幅度将较为有限。预计下半年，甲醇供应延续宽松态势，受益于国内反内卷及煤制甲醇新建项目政策限制，供需结构有望改善，下游需求或呈阶段性回暖，市场整体走势以震荡为主。丙烯腈方面，供过于求的格局预计将进一步加剧，丙烯腈价格若要出现好转，需依赖国内主流企业降低装置负荷。公司首席执行官饶仕才先生表示：「2025年下半年，公司将聚焦完善设备管理体系，保障装置安全平稳运行，夯实本质安全基础；同时着力打造品质定位，抓好拓市拓销，提升营销创效能力。此外，公司将推进『人工智慧+』行动，加速数智技术与实体经济的深度融合，推动富碳天然气利用重点项目研究及强化传播矩阵管理，持续提升品牌价值。」有关中海石油化学股份有限公司中海石油化学股份有限公司(「中海石油化学」)是专门从事化肥及相关化工产品开发、生产及销售的上市企业，是化肥产能及产量最大的中央企业，为从事石油和天然气勘探、开发、生产及销售的中国海洋石油集团有限公司之子公司。中海石油化学于2006年9月29日在香港联合交易所主板挂牌上市，股份编号：3983。公司现有生产设施位于中国海南、湖北及黑龙江，总设计年产能达184万吨尿素、130万吨磷复肥(磷酸一铵、磷酸二铵和复合肥)、140万吨甲醇、20万吨丙烯腈及7万吨MMA，公司并拥有位于海南省东方市的设计年吞吐能力为1,828万吨的深水港口。中海石油化学的企业品牌价值持续提升，2025年达72.58亿元，创历史新高。2025年，中海石油化学荣膺第四届国际绿色零碳节暨ESG领袖峰会『2025 ESG 典范企业奖』。如欲查询更多公司资料，请浏览公司网站 www.chinabluechem.com.cn。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- Langham Place Mall marks 20 years of excellence "Stay Local, Trend Global", becoming a brand hotspot with Chiikawa Ramen Buta’s premier overseas debut- Three Garden Road successfully concluded all 2025 expirations with high retention rate- Langham Place Office Tower unveiled “6D Wellness” concept, an innovative concept strengthening its positioning as a one-stop wellness and lifestyle hub- Lower Hibor reduced interest expenses; all 2025 debt successfully refinancedHONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Champion Real Estate Investment Trust (stock code: 2778), the owner of Three Garden Road and Langham Place, announces its financial results for the six months ended 30 June 2025.Summary of financial results 1H 20251H 2024ChangeTotal Rental Income (HK$ million)1,0291,115- 7.6%Net Property Income (HK$ million)859954- 10.0%Distributable Income (HK$ million)476544- 12.6%  Distribution per unit (HK$)0.07010.0809- 13.3% 30 Jun 202531 Dec 2024ChangeGross Value of Portfolio (HK$ million)58,09860,104- 3.3%Net Asset Value per unit (HK$)6.797.16- 5.2%Gearing Ratio24.5%23.7%+ 0.8ppOverviewWhile the global economy faced headwinds from trade tensions and geopolitical conflicts in the first half of 2025, Hong Kong’s market sentiment found support from several positive developments. A stock market revival, declining Hong Kong Interbank Offered Rates (“Hibor”) in the second quarter, stabilised residential sales and a steady tourism rebound helped counterbalance external pressures. However, persistent outbound travel by residents continued to divert spending elsewhere, weighing on local retail sales. Meanwhile, the office leasing market remained subdued, reflecting an ongoing imbalance between supply and demand. Against this backdrop, distributable income of the Trust decreased by 12.6% to HK$476 million and distribution per unit (“DPU”) declined by 13.3% to HK$0.0701.Ms. Christina Hau, Chief Executive Officer of Champion REIT (Left), Ms. Amy Luk, Investment and Investor Relations Director of Champion REIT (Right)Three Garden RoadAlthough overall office leasing momentum in Central remained suppressed, we received increased leasing inquiries amid rising financial market activities, with demand primarily from finance-related firms. Several new small-sized tenants, including family offices, committed to establishing operations in the property, while an existing banking sector tenant expanded its presence here. Occupancy of Three Garden Road office was 80.7% as at 30 June 2025. Rental income of the property fell 5.4% to HK$540 million (2024: HK$571 million). We advanced lease renewal efforts, successfully concluding all 2025 expirations with a high retention rate, including several anchor tenant renewals. For 2026, over 70% of the expiring leases have already been renewed.Langham Place Office TowerDuring the reporting period, Langham Place Office Tower launched “6D Wellness” YouTube channel to strengthen the property’s positioning as a one-stop wellness and lifestyle hub. As at 30 June 2025, lifestyle (wellness) tenants comprised 68% of the property’s tenant mix. Occupancy of Langham Place Office Tower remained stable at 86.9% as at 30 June 2025. The expanded co-working space introduced a Social Wellness Hall for wellness workshops and events, resonating with the property’s wellness positioning. Market rental continued to face challenges with rental income dropped by 9.1% to HK$151 million (2024: HK$166 million).Ms. Christina Hau, Chief Executive Officer of Champion REITLangham Place MallAs Langham Place Mall celebrates its 20th anniversary in 2025, it continues to embrace its bold “Stay Local, Trend Global” vision. Through immersive experiences and exclusive merchandise, we successfully attracted record crowds and drove sales, establishing new single-day footfall record in August. Recently, fashion brand BENLAI, marking its inaugural Hong Kong flagship presence in the mall, and Umbro’s first in town lifestyle themed pop-up store, have commenced operations. Further elevating the mall’s offerings, Chiikawa Ramen Buta has chosen this location for its premier overseas outlet, shortly becoming a hotspot since opening. Occupancy of Langham Place Mall remained high at 99.2% as at 30 June 2025, reaching full committed occupancy currently. Since changing consumer behaviour has posed challenges for tenants, rental income of the mall declined to HK$338 million (2024: HK$378 million).DistributionDistributable income of the Trust decreased by 12.6% to HK$476 million (2024: HK$544 million) and DPU declined by 13.3% to HK$0.0701 (2024: HK$0.0809). Based on the closing unit price of HK$2.08 recorded as at 30 June 2025, the total DPU represented an annualised distribution yield of 6.7%.Asset ValueThe appraised value of the Trust’s property portfolio was HK$58.1 billion as at 30 June 2025, declining by 3.3% from HK$60.1 billion as at 31 December 2024.SustainabilityWe continue to create shared values across our ecosystem through initiatives that drive climate resilience, build meaningful connections, and support community wellness. During the reporting period, we implemented an AI-powered chiller optimisation system at Three Garden Road, achieving 6.1% annual energy savings. Through our EcoChampion Pledge programme, we bring both office and retail tenants together in the shared commitment to fulfilling measurable environmental goals. Furthermore, Our Champion REIT ESG Gala, themed "Innovation - Inspiration · Integration", brought together over 1,000 tenants and business partners to advance sustainable operations and inclusive practices.OutlookAlthough Hong Kong retail sector has returned to growth and the financial market has rebounded, the overall operating environment of the Trust is expected to remain challenging in the rest of 2025. While lower HKD interest rates should reduce interest expenses, negative rental reversion will likely continue to suppress rental income and reduce distributions compared to last year. We remain committed to maintaining operational agility to navigate this competitive market landscape.About Champion REIT (stock code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income- producing office and retail properties. The Trust focuses on Grade A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust has been awarded the top five-star rating by GRESB since 2023. Champion REIT is managed by Eagle Asset Management (CP) Limited, a member of the Great Eagle Group.Website: www.championreit.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Susan Rohac, ICD.D, built one of Canada's largest and most active climate funds, overseeing a Pan-Canadian team of investment professionals and managed a portfolio over $1 billion in assets.Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 18, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the appointment of Mrs. Susan Rohac, ICD.D, to its Board of Directors, effective immediately. Mrs. Rohac replaces long-serving director Robin Dow, who has stepped down from the Board to focus on personal pursuits and other interests, and will continue to support a smooth transition.Susan Rohac had an extensive thirty-four (34) plus year career at the Business Development Bank of Canada ("BDC"), holding various leadership roles. Her final role was as Managing Partner of the Climate Tech venture capital fund, which she held from 2017 to May 2025. In this role, she oversaw a pan-Canadian team of investment professionals and managed a portfolio of over $1 billion in assets. This portfolio included a fully deployed $600 million fund I and a $500 million fund II launched in 2022 that focused on investing in Canada's most promising clean technology companies. Susan has invested in a diverse range of climate technologies across various sectors, including energy, mobility, built environment, carbon management, and industry & resource space, including advanced materials and critical minerals. In 2024, Susan was recognized as a Climate Leader by the Clean50 and received the Clean16 award. She holds undergraduate degrees in both science and finance and an executive MBA from the University of Ottawa. In 2024, she also obtained her ICD.D governance designation from the University of Toronto. Passionate about the environment and climate technologies, Susan currently sits on several governance and advisory boards and is actively involved with a few organizations that are aligned with her interests."We are delighted to welcome Susan to our Board," said Jeff York, Founder and Chairman of Focus Graphite. "She brings a strong track record in corporate finance and scaling industrial technologies, with a deep appreciation for Canada's critical minerals opportunity. Her experience and connections in the industry will be invaluable.""I am honored to join Focus Graphite at such an important moment," said Ms. Rohac. "The shift to green energy is driving unprecedented demand for secure supplies of critical minerals, and Canada has an opportunity to lead in building a reliable, sustainable graphite supply chain here at home. Beyond batteries, graphite is essential for advanced manufacturing and defense applications that underpin national security. I look forward to working with the team to help strengthen North America's self-sufficiency and reduce reliance on foreign supply."Mr. York added, "On behalf of the company and our shareholders, I want to thank Robin for his years of service and leadership. His guidance helped position Focus for its next phase of growth."Focus Graphite is also pleased to announce its participation in the Canadian Critical Minerals Investment Forum, an international trade mission organized by Natural Resources Canada and Invest in Canada. The event will be held in Tokyo, Japan from August 26-28, 2025, and in Korea from August 29-30, 2025. Focus Graphite is one of only two Canadian graphite companies attending the Forum, which brings together global investors, government officials, and industry leaders to advance critical minerals partnerships. In addition to the Forum, the Company will hold a series of bilateral meetings in both countries to further strategic discussions with potential partners and customers.On August 14th, 2025, Focus Graphite visited its Lac Knife project site near Fermont, Québec. The Company was pleased to host a representative from Korea Mine Rehabilitation and Mineral Resources Corporation ("KOMIR") alongside its newest board member, Susan Rohac. During the visit, Focus also met with officials from the Town of Fermont to provide a corporate and project update, highlighting recent progress and outlining the Company's pathway toward advancing Lac Knife to a fully permitted mining operation.In connection with Ms. Rohac's appointment, the Company has granted her 250,000 stock options pursuant to its Stock Option Plan. The options are exercisable at a price of $0.35 per common share and will expire on August 17, 2030. They are subject to the terms of the Plan as well as the policies of the TSX Venture Exchange.Image 1: Focus Graphite executives, IOS Geosciences, and a representative from KOMIR visit the Lac Knife project near Fermont, Québec, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_001full.jpgImage 2: Focus Graphite executives and IOS Geosciences visit with representatives from the Town of Fermont, QC, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_002full.jpgAbout Invest in CanadaInvest in Canada is Canada's foreign direct investment (FDI) attraction and promotion agency. We find the best to invest in Canada. This means working with our partners across the country and worldwide to attract global companies and support their expansion plans in Canada.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the advancement of the Lac Knife project through permitting and development activities, the Company's participation in the Canadian Critical Minerals Investment Forum in Japan and Korea and the potential outcomes of related bilateral meetings, the anticipated benefits of Ms. Rohac's appointment to the Board of Directors, the Company's ability to establish strategic partnerships and secure future customers, and its positioning as a near- and long-term supplier of specialty graphite materials within North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262819 Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - uSMART Securities, a strategic investment of Chow Tai Fook (Holding) Limited, is pleased to announce the official launch of its new branches at Hong Kong’s Lok Ma Chau MTR Station and West Kowloon High-Speed Rail Station, strategically positioned to serve cross-border clients and passengers. A grand opening ceremony was held at the West Kowloon branch, attended by prominent financial professionals.At the event, Mr. Neo Lee, Executive Director of uSMART Securities, stated: "To provide more accessible financial services, uSMART Group plans to open 12 service centers across Hong Kong and Singapore this year, covering key districts such as Tsim Sha Tsui, Causeway Bay, Tsuen Wan, Sheung Shui, and Sheung Wan. This expansion will enhance our regional service network and bring us closer to our local clients."“As a No.1 Hong Kong Funded Fintech Brokerage^ with over 800,000 users globally, uSMART Securities is committed to elevating the investment experience. Our new branches offer comprehensive services, including investment consultations, account opening assistance, and personalized support for seniors and beginners to navigate our trading app," added Neo Lee.(From left to right: Business Development Director of uSMART Securities, Marketing Director of uSMART Securities, Executive Director of uSMART Securities, Head of Research and Asset Management of uSMART Securities and Business Development Manager of uSMART Securities)During the launch period, clients can enjoy exclusive mystery gift upon check in new shop, along with complimentary beverages, and mobile charging services. New customers who open an account at the branch will receive additional rewards. To further penetrate the Hong Kong market, uSMART Securities has introduced its "Trader Account", offering lifetime 0 commission for US and HK Stocks, plus 0 commission for US options trading for local clients.As a token of appreciation, uSMART Securities is rolling out a suite of 0 fee promotions for both new and existing clients, including:1)0% margin interest for IPO subscriptions | 0 handling fees for cash subscriptions2)0 commission & 0 platform fees for 100+ Hong Kong ETFs (covering high-dividend, virtual asset, and index ETFs)3)$0 cost to invest in US & HK stocks Monthly Investment Plan (no commission, platform fee, custody fee, and dividend collection fee)These offers are designed to support investors with different short, medium, and long-term investment strategies, ensuring all uSMART Securities clients could enjoy.Neo Lee also revealed that uSMART Group is actively expanding its teams in Hong Kong and Singapore to strengthen competitiveness. The Group’s newly established Manhattan office in New York will focus on serving hedge funds, family offices, and pre-IPO companies with institutional brokerage, asset allocation, and investment banking advisory services, reinforcing its leadership in fintech brokerage.Moving forward, uSMART Securities remains dedicated to customer-centric innovation, delivering premium offline services and cutting-edge financial solutions for global investors.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of May 2025.Terms and conditions apply.About uSMART:Strategic investments from Chow Tai Fook (Holding) Limited, uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past seven years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (Shanghai,Shenzhen,and Hong Kong stock connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.com/For any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

重点成果- 期内，集团共有2个创新产品获中国国家药品监督管理局（「NMPA」）批准上市，分别为普坦宁（美洛昔康注射液(II)）和安启新（注射用重组人凝血因子VIIa N01）。- 2025年上半年，集团创新产品收入达到人民币78亿元，同比增长27.2%。除创新产品外，集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持正增长。- 截至2025年6月30日，集团共有37个肿瘤领域、7个肝病╱代谢领域、13个呼吸系统领域、和6个外科╱镇痛领域的创新候选药物处于临床申请及以上开发阶段。其中，2个肿瘤领域、1个外科╱镇痛领域产品处在上市申请阶段；11个肿瘤领域、1个肝病╱代谢领域、3个呼吸系统领域、1个外科╱镇痛领域的创新候选药物处于临床III期；另有13个肿瘤领域、6个肝病╱代谢领域、12个呼吸系统领域、6个外科╱镇痛领域的生物类似药或仿制药候选药物处于临床申请及以上开发阶段。- 福可维（盐酸安罗替尼胶囊）是一种新型小分子多靶点酪氨酸激酶抑制剂，目前已获批9个适应症，另有3个适应症处于上市申请阶段。此外，安罗替尼还有多项新适应症处于III期临床研究阶段，包括一线非鳞状非小细胞肺癌、一线胰腺癌等，预计将在未来两年逐步递交上市申请。- 2023-2024年，集团共有5款肿瘤领域的国家1类创新药获批上市，分别为：亿立舒（艾贝格司亭α注射液）、安得卫（贝莫苏拜单抗注射液）、安柏尼（富马酸安奈克替尼胶囊）、安洛晴（枸橼酸依奉阿克胶囊）和安方宁（格索雷塞片）；以及4款肿瘤领域的生物类似药获批上市，分别为：安倍斯（贝伐珠单抗注射液）、得利妥（利妥昔单抗注射液）、赛妥（注射用曲妥珠单抗）和帕乐坦（帕妥珠单抗注射液）。该等产品在2025年上半年快速放量，成为集团收入增长的重要贡献品种。- 拉尼兰诺（泛PPAR激动剂）是一种口服小分子药物，用于治疗代谢功能障碍相关脂肪性肝炎（MASH），目前正在全球开展III期临床试验，已完成全部受试者入组。2023年7月，拉尼兰诺被药品评审中心「CDE」纳入突破性治疗药物程序。拉尼兰诺是中国第一个进入临床III期的MASH口服药物，有望填补中国市场空白。- 天晴速畅（吸入用布地奈德混悬液）是中国首款获批上市的布地奈德雾化剂型仿制药，打破了国内市场长期被原研垄断的局面，为国内气道慢性炎症患者带来了兼具有效性、安全性与经济性的高端制剂产品。该产品已被纳入集采范围，集团及时采取了一系列主动管理措施，包括管道下沉、拓展市场覆盖和集采外市场的二次开发。- 泽普思╱得百安（氟比洛芬凝胶贴膏）是中国首个获批上市的国产凝胶贴膏，连续多年蝉联外用镇痛市场份额第一位。集团聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求，推动泽普思/得百安销售额持续快速增长。集团开发的第二代氟比洛芬贴剂预计将在一年内获批上市。通过剂型升级，二代产品可显著提高药物透皮吸收度，增强贴膏粘附性，从而提升患者的依从性。香港，2025年8月18日 - (亚太商讯 via SeaPRwire.com) - 中国领先的创新研发驱动型医药集团-中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2025年6月30日止6个月（「期内」）之未经审核财务业绩。回顾期内，集团收入同比增长10.7%至约175.7亿元（人民币，下同）。来自持续经营业务之归属于母公司持有者应占盈利财务报表所示约33.9亿元，同比增长约140.2%，基于归属于母公司持有者应占盈利计算之每股盈利约18.82分。归属于母公司持有者盈利同比显著增长主要受惠于本期间收入明显增长及股息收益和投资公允价值变动收益明显增长。归属于母公司持有者之基本溢利（非香港财务报告准则指标）约30.9亿元，同比增长约101.1%。集团流动资金保持充裕，期内有计入流动资产之现金及银行结余约111亿元、计入非流动资产之银行存款约101亿元，理财管理产品总额约92.9亿元，资金储备合共约304.9亿元。董事会建议派发中期股息每股5港仙（2024上半年：3港仙）。销售：研发创新动能强劲，多领域销售成果持续放量集团一直以来重视研发，持续加大投入以提升研发质效，研发实力显著增强，驱动销售收入持续增长，成果丰硕。期内，抗肿瘤用药之收入同比增加24.9%，达约66.9亿元，占集团收入约38.1%。外科／镇痛用药之收入同比增加20.2%，达约31.1亿元，占集团收入约17.7%。肿瘤领域，集团全面布局非小细胞肺癌领域，覆盖多种分型的全线治疗，EGFR/cMet双抗TQB2922即将启动二线非小细胞肺癌III期临床，EGFR/cMet双抗ADC TQB6411 I期临床正在入组，两款产品进度均位于中国前列；深度布局乳腺癌三大亚型， CDK2/4/6抑制剂库莫西利胶囊有望成为HR+/HER2-乳腺癌的BIC疗法，HER2双抗ADC TQB2102较DS-8201潜在安全性优效，多个适应症正在同步拓展，其中三项乳腺癌III期快速推进；系统布局消化道领域结直肠癌、胃癌、胰腺癌、肝癌等核心癌肿，LM-108(CCR8单抗)、TQB2868(PD-1/TGF-β双功能融合蛋白)研发进度全球最快，且目前临床数据展示出了极大潜力。于外科╱镇痛领域，集团持续聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求。期内，集团推动泽普思销售额持续快速增长，而开发的第二代氟比洛芬贴剂预计将在一年内获批上市。同时，2025年5月获批的普坦宁凭借长效镇痛、安全性优异等优势，有望成为该领域新的增长动力。研发：全力以赴推动创新产品开发，加大研发的资金投入于报告期内，集团共有2个创新产品获NMPA批准上市，分别为普坦宁（美洛昔康注射液(II)）和安启新（注射用重组人凝血因数VIIa N01）。2025年上半年，集团创新产品收入达到人民币78亿元，同比增长27.2%。除创新产品外，集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持正增长。一直以来，集团十分重视研发，不断提升研发水平和速度，并视其为可持续发展的基础，加大研发的资金投入。截至二零二五年六月三十日止六个月，研究与开发成本约人民币318,756万元，占本集团收入约18.1%，连同已资本化的研发总开支出在内，约95.7%已计入损益表中。展望：深化创新与国际化布局，加速构建全球医药创新竞争力当前，中国医药产业正迎来历史性发展机遇。在国家创新驱动发展战略的指引下，我国生物医药创新能力显著提升，创新药研发已从「跟跑」逐步迈向「并跑」甚至「领跑」阶段。中国创新药不仅在本土市场构建起强劲的增长势能，更在全球市场逐步崭露头角，日益获得广泛认可，已成为全球医药创新产业中不可替代的重要力量。作为行业领军企业，集团深耕肿瘤、肝病╱代谢、呼吸系统及外科╱镇痛四大核心治疗领域，专注创新，服务病患，目标成为全球领先的制药企业。集团深耕中国市场，同时将战略视野投向全球市场，以国际化加速创新发展。同时，集团大力推进全球战略合作布局，通过商务拓展（BD）、战略收购等多元合作路径，快速充实创新管线储备，强化核心技术平台。2025年7月，集团宣布全资收购礼新医药。礼新医药拥有全球领先的抗体发现和ADC技术平台，包括肿瘤微环境特异性抗体开发平台 (LM-TME™)、针对难成药靶点的抗体开发平台（LM-Abs™），新一代抗体偶联药物平台（LM-ADC™）、以及免疫细胞衔接器平台（LM-TCE™）。此次收购将进一步增强集团的创新研发能力，加速集团的创新业务增长。此外，礼新医药卓越高效的研发团队将加入集团，进一步强化集团的创新研发人才储备，为持续产出高水平创新成果提供保障，助力创新生态的长远发展。未来，本集团将继续聚焦创新，提升四大治疗领域的研发效率与质量，加快国际化步伐，力争实现业务快速发展与业绩稳步提升。有关中国生物制药有限公司（股票编号：1177）中国生物制药，连同其附属公司，是中国领先的创新研究和研发驱动型医药集团，业务覆盖医药研发平台、智慧化生产和强大销售体系全产业链。产品包括多种生物药和化学药，在肿瘤、肝病/代谢、呼吸系统、外科/镇痛四大治疗领域处于优势地位。公司于2000年在香港联交所上市，2013年入选MSCI全球标准指数之中国指数成分股；2018年入选恒生指数成分股；2020年入选恒生沪深港通生物科技50指数成分股、恒生中国(香港上市)25指数。中国生物制药连续七年荣登美国权威杂志《制药经理人》发布的「全球制药企业TOP50」，连续三年获评《福布斯》(亚洲) 「亚太最佳公司50强」。有关中国生物制药的进一步资料，请浏览: www.sinobiopharm.com Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月19日 - (亚太商讯 via SeaPRwire.com) - 由周大福控股战略入股的uSMART盈立证券欣然宣布香港落马洲港铁站，西九龙高铁站分行已正式投入服务，涵盖陆路出入境和高铁枢纽客戶群。为庆祝这一里程碑，盈立证券今日在西九龙分行举行简单而隆重的开幕仪式，并邀得不少财经界精英出席，令活动生色不少。开幕礼上，盈立证券执行董事李建翰先生（Neo Lee）表示：「为提供更便捷的金融服务方便区内居民，盈立集团计划年内于香港及新加坡两地社区内开设分行，连同总部客户专区，服务点增至12个，进驻尖沙咀，铜锣湾，荃湾，上水及上环等核心地区，全面强化区域服务网络，拉近与本地客户的距离，提供更贴心的服务。」「作为港资科技券商No.1^，全球超过800,000用户，盈立证券十分重视提升用户的投资体验，本次开立分行不但提供综合服务，包括投资咨询，办理开户等，还协助长者及初学者处理开户流程，学习App使用方法等，借此深化本地市场，满足客户对相关服务的殷切需求。」Neo Lee续说。(左起︰盈立证券业务拓展总监邓永麟先生、盈立证券香港市场部总监黄晓霖小姐、盈立证券执行董事兼机构业务负责人李建翰先生、盈立证券资产管理兼投研部总监蒋雄先生及盈立证券业务拓展经理林向尊先生)新开张时间内，前往分行打卡即可获赠神秘礼品1份，同时亦可免费享用饮料及手机充电服务，于分行开户更可额外获得丰富礼品。为进一步开拓香港市场，盈立证券推出「Trader账户」，香港本地客户专享美港股一世免佣，美股期权0佣优惠。为感谢客户的支持，uSMART盈立证券亦同时提供多项真全免优惠，不论新客户或现有客户，均可享受，绝无取巧，优惠包括：1)IPO融资认购0息│现金认购0手续费；2)>100只港股ETF 0佣0平台费（当中包括近期投资者热爱的高息股ETF，虛擬資產相關ETF及指数ETF等）；3)月供美港股0佣0平台费0存管费及免代收股息税以上优惠旨在满足短线，中线及长线投资策略，让持有uSMART盈立证券账户的客户均能受惠。Neo Lee在开幕礼上透露，集团正积极增聘人手，扩充香港及新加坡团队，以支持及推进业务发展，提高本地市场竞争力；而集团旗下的美国办公室亦正式进驻至世界金融中心-纽约曼哈顿城中心，并将专注于对接对冲基金，家族办公室及拟赴美上市企业，提供机构经纪、资产配置及投行咨询等专业服务，巩固全球金融科技券商领域的领先地位。展望未来，uSMART盈立证券秉持以客为本的理念，为更多本地投资者提供星级投资体验及优质线下服务，同时亦致力推动金融服务的创新与升级，为全球客户创造更多价值。^"港资科技券商No.1"是取自捷利金融云截至2025年5月为止连续超过一年数据，uSMART盈立证券为香港本地港资互联网券商月成交总额排行第1。优惠受条件及细则约束关于uSMART盈立证券：由周大福控股战略入股的盈立证券是一间领先科技港资券商，成立于2018年，7年来凭借卓越的战略规划和创新能力，致力于将科技与金融深度融合，业务范围涵盖证券，资产管理，财富管理等领域，为全球投资者独家研发了金融证券交易平台uSMART HK APP和uSMART SG APP，分别由盈立证券（香港）和盈立证券（新加坡）提供服务。集团APP支持港股，美股，A股（沪深港通），新加坡股票，日本股票，英国股票，美股期权，ETF，基金，债券，资管，结构化票据，期货，加密货币，贵金属，黄金和外汇等多元化的投资交易服务，此外更为超高净值个人与家族，企业提供度身订制服务，打造全方位综合性资产管理解决方案。详情可浏览 https://hk.usmartglobal.com/传媒查询：黄晓霖Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company's exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth MomentumAt the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional GrowthAccording to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets - International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - CENTRESTAGE – the annual gala event for the Asian fashion industry – takes place from 3 to 6 September 2025 at the Hong Kong Convention and Exhibition Centre (HKCEC). Unveiling a grand celebration of style for its 10th anniversary edition, this year’s CENTRESTAGE sees a record participation of some 260 brands from 24 countries and regions. The programme features more than 40 events, including around 30 fashion shows and parades – another record for the event. Organised by the Hong Kong Trade Development Council (HKTDC) and sponsored by the Cultural and Creative Industries Development Agency (CCIDA) of the Government of the Hong Kong Special Administrative Region (HKSAR), the four-day showcase is open to industry professionals and the public free of charge, welcoming visitors from Hong Kong, Mainland China and overseas to experience the charm and creativity of Asia’s fashion capital.Sophia Chong, Deputy Executive Director of the HKTDC, said: “Over the past decade, CENTRESTAGE has become the perfect meeting point for fashion brands and designers from across the globe, and Asia in particular, to showcase their latest creations. As the event celebrates its 10th anniversary, we are truly privileged to welcome internationally acclaimed couturier Guo Pei to present a collection at CENTRESTAGE ELITES, marking her first solo couture show in Hong Kong. As the flagship fashion event for Asia, CENTRESTAGE not only celebrates virtuosity in design and craftsmanship, but also propels both local and international brands into the broader Asian market, supporting the vigorous development of the local fashion industry and reinforcing Hong Kong’s status as a global fashion hub and world-class East-meets-West centre for cultural exchange.”This year’s CENTRESTAGE welcomes fashion brands from across the globe, including pavilions from the United Kingdom, Czech Republic, Japan and Thailand. The UK is participating for the first time as the "Partner Country" of CENTRESTAGE, showcasing unique creations from various British designers. Globally acclaimed fashion maestro Jimmy Choo will not only attend CENTRESTAGE in person but also spotlight his visionary initiative – the Jimmy Choo Academy – showcasing works by emerging designers nurtured by the Academy. The  Czechia pavilion will present personalised fashion labels that incorporate art-glass design; the Japan pavilion will spotlight emerging designers and brands, showcasing the creative force of Japan’s new generation; and the Thailand pavilion returns on an unprecedented scale, leading more than 40 brands to the show and expressing the rich diversity of Southeast Asian style. Brands from South Korea, Singapore and other countries will also exhibit their collections at the fair.CENTRESTAGE ELITES sees Guo Pei’s first solo couture show in Hong KongThe prestigious opening event, CENTRESTAGE ELITES, takes place on 1 September at M+ in the West Kowloon Cultural District, with internationally acclaimed couturier Guo Pei presenting her first solo couture show in Hong Kong. Guo Pei was the first Chinese designer invited to join the Fédération de la Haute Couture et de la Mode (FHCM) while also consecutively presenting 10 showcase collections in Paris. She previously participated in HKTDC Hong Kong Fashion Week for Fall/Winter in 2010, closing the Hong Kong Fashion Extravaganza with a spectacular finale.For CENTRESTAGE ELITES, Guo will present 30 one-of-a-kind couture creations under the theme "Gilternity: An Everlasting Radiance", drawing inspiration from the dazzling, fleeting moment of flowing molten gold. Fusing traditional craftsmanship with modern art, the collection epitomises her unparalleled artistry and technical mastery. In a gesture that honours both tradition and innovation, Guo has invited students from Hong Kong Polytechnic University (PolyU) to collaborate on the opening piece for the show.This grand occasion will be livestreamed on the CENTRESTAGE website and Instagram, the HKTDC’s YouTube channel, Facebook and official pages, and across multiple platforms including ViuTV Facebook and Yahoo HK. On the second day of the event (4 September), Guo Pei will appear in person for a master sharing session, offering rare in-person insights into her creative journey and design philosophy.Fashion Hong Kong Runway Show celebrates designers’ creative journeyOn the evening of 3 September, the Fashion Hong Kong Runway Show will take the stage under the theme "A Decade in Design: What is Seen' What is Felt'", exploring Hong Kong designers’ creative journeys. Four Hong Kong designer brands – ANGUS TSUI, ARTY:ACTIVE, IP AXIS INDUSTRIALSTUDIO and selfFab. – will showcase their innovative collections, merging visual impact and emotional narrative to spotlight the unique creativity of Hong Kong fashion design.Six thematic zones showcase sustainability and diversityCENTRESTAGE will be staged across six distinctive thematic zones, each offering its own unique appeal. The new Accessories Zone will present an array of fashion jewellery, handbags, footwear and other refined fashion accents, where style and function are seamlessly intertwined. The Athleisure Zone will champion activewear that unites aesthetics with practicality, reflecting the growing prominence of sports-inspired looks. The Craftsmanship Zone will showcase exquisite techniques and artisanal mastery that pay homage to heritage skills, while the Contemporary Zone will unveil forward‑thinking, avant‑garde creations from cutting‑edge designers. The Urban Zone will spotlight youth‑driven trends, including labels such as Petrolhead, helmed by artist Louis Cheung, which fuses motorcycle culture with a streetwear edge. Completing the lineup, the Circular Fashion Zone will advocate the possibilities presented by sustainable style, headlined by the 15th Redress Design Award Final at which the winning eco‑conscious collections will be showcased, promoting the industry’s focus on environmentally friendly design.The four-day fair will present a rich variety of happenings, including student showcases from PolyU’s School of Fashion and Textiles and the Hong Kong Design Institute, as well as an interdisciplinary exhibition from the Fashion Farm Foundation that combines music, art, product design and intangible cultural heritage, featuring traditional crafts such as gold-thread embroidery in bridal gowns and the making of Canton silk. A record-breaking total of 28 fashion shows will be held throughout CENTRESTAGE, featuring brands such as 112 mountainyam, CAMMIE CHAN CHEONGSAM, DorisKath, and KOWLOON CITY BOY that showcase the vibrant energy of the fashion industry.LOCAL POWER 2025, a cross-cultural project curated by Asian New Generation Creativity Design Association, will officially launch during CENTRESTAGE. This initiative will bring together designers from Hong Kong and Korea, presenting a thoughtfully curated exhibition and runway show that will help to foster cultural and creative exchanges between the two places. “THREAD OF CREATIVITY – Fashion Design Competition 2025" and Knitwear Innovation and Design Society Limited (KIDS) featuring the Young Knitwear Designers' Contest 2025 will also be held during the fair period.The HKTDC will continue to invite buyers from around the world to source at CENTRESTAGE, including major multi-brand stores such as WDLT 117 Apparel Inc. from Canada, Zalora from Indonesia, Sugar Srl from Italy and Hankyu Hanshin Department Stores from Japan.Spotlighting new talent at the YDCThe grand finale of CENTRESTAGE 2025 on Saturday, 6 September will be the Hong Kong Young Fashion Designers’ Contest (YDC), dedicated to discovering and nurturing new local talent. This year's competition will continue to promote a spirit of innovation and experimentation, allowing participants to fully showcase their creativity while injecting fresh talent into the industry. Charles Jeffrey, the designer behind the London label Charles Jeffrey LOVERBOY, has been invited as guest judge, joining a panel of other industry professionals to select winners from the 10 finalists vying for four major awards: Champion, Excellence Award, Best Art Direction and My Favourite Collection. Members of the public are invited to participate by casting votes online (https://bit.ly/YDC2025_IG_Vote_Now) for their favourite collection. Designer brands JESSE LEE and gnastiy.com, both former participants in the YDC, will showcase their new season special collections alongside guest performers at this year's YDC finale.CENTRESTAGE will be staged in parallel with the HKTDC Hong Kong Watch & Clock Fair and Salon de TIME, with visitors able to view the latest products from some 400 watch and fashion brands at the same venue. The fairs will also feature the CENTRESTAGE x Watch & Clock Lucky Draw. The brand-new CENTRESTAGE Instagram account (@centrestage_hktdc) is now officially live and will be updated with the latest event information and fashion trends. Everyone is welcome to follow and stay closely connected with all the latest happenings at CENTRESTAGE.Photo download: https://bit.ly/47uYUFOSharing highlights of this year’s CENTRESTAGE at today’s press conference are Sophia Chong, Deputy Executive Director of the HKTDC (second right); Katherine Fang, Chairman of the HKTDC Garment Advisory Committee (second left); Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (first right); and local fashion designer Angus Tsui (first left).The grand opening event, CENTRESTAGE ELITES, will be held on 1 September at M+ in the West Kowloon Cultural District. Internationally acclaimed couturier Guo Pei will present her first-ever couture show in Hong Kong. Her "Gilternity: An Everlasting Radiance" collection was previewed at today’s press conference.Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (left), and artist Marf Yau (right) wear creations from Patrick McDowell, a brand featuring at the UK Pavillion, at the CENTRESTAGE press conference.Local designer Angus Tsui (left) and artist/emcee Thor Lok (right) showcase a fashion piece designed by Angus Tsui.Websites- CENTRESTAGE: https://www.hktdc.com/event/centrestage/en- CENTRESTAGE ELITES: https://www.hktdc.com/event/centrestage/en/centrestage-elites- CENTRESTAGE Instagram: https://www.instagram.com/centrestage_hktdc/?hl=en- Fashion Hong Kong: https://www.fashionhongkong.com.hk/en- Hong Kong Young Fashion Designers' Contest (YDC): www.fashionally.com/enMedia enquiriesBest Crew Public Relations & MarketingDiana Tang Tel: (852) 9199 6723 Email: diana.tang@bestcrewpr.comReni Kwok Tel: (852) 6291 4283 Email: reni.kwok@bestcrewpr.comHKTDC Communication and Public Affairs Department:Sharon Ha Tel: (852) 2584 4575 Email: sharon.mt.ha@hktdc.orgKaty Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout the HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. About Cultural and Creative Industries Development Agency (CCIDA)The Cultural and Creative Industries Development Agency (CCIDA) established in June 2024, formerly known as Create Hong Kong (CreateHK), is a dedicated office set up by the Government of the Hong Kong Special Administrative Region (HKSAR Government) under the Culture, Sports and Tourism Bureau to provide one-stop services and support to the cultural and creative industries with a mission to foster a conducive environment in Hong Kong to facilitate the development of arts, culture and creative sectors as industries. Its strategic foci are nurturing talent and facilitating start-ups, exploring markets, promoting cross-sectoral and cross-genre collaboration, promoting the development of arts, culture and creative sectors as industries under the industry-oriented principle, and promoting Hong Kong as Asia’s creative capital and fostering a creative atmosphere in the community to implement Hong Kong’s positioning as the East-meets-West centre for international cultural exchange under the National 14th Five-Year Plan.CCIDA’s website: www.ccidahk.gov.hkDisclaimer: The Government of the Hong Kong Special Administrative Region provides funding support to the project only, and does not otherwise take part in the project. Any opinions, findings, conclusions or recommendations expressed in these materials/events (or by members of the project team) are those of the project organisers only and do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the CreateSmart Initiative Secretariat or the CreateSmart Initiative Vetting Committee. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳，2025年8月19日 - (亚太商讯 via SeaPRwire.com) - 8月18日，康哲药业发布2025年中期业绩，公司营收和利润同比均实现增长，战略转型成效初显。报告期内，公司实现营业收入约40.0亿元（人民币，下同），同比增长10.8%。若全按药品销售收入计算则营收约46.7亿元，同比增长8.9%。实现净利润约9.3亿元，同比增长3.1%。具体来看，康哲药业已走出国采阴霾，业绩将回归持续上升轨道。公司主要非国采独家/品牌产品及创新产品全按药品销售收入合计约29.0亿元，同比增长20.6%，占总收入比重升至62.1%。公司独家/品牌产品、创新产品竞争格局良好、增长可预期性强，目前已成为拉动业绩向上的主力军。根据业绩公告，公司自2018年起擘画"新康哲"转型蓝图，以"产品创新、商业革新、国际拓展"三大战略为支柱，构建可持续的第二增长曲线。行至2025年上半年，良好的经营业绩及创新成果持续落地，证实战略升级已逐步兑现为硬核战果。"新产品"战略推动创新价值兑现 夯实增长后劲立于公司三大战略之首的"产品创新"战略，依托"海外授权+国内合作+自主研发"三维创新机制，持续注入高价值短、中、长期管线，成为驱动增长的重要引擎。目前，创新战略已进入持续收获期，新产品正不断释放商业与临床价值。截至目前，公司已有5款创新药成功于中国实现商业化；2025年内，芦可替尼乳膏和德昔度司他片两款创新产品亦有望获批上市。芦可替尼乳膏是美国FDA以及欧洲EMA批准的首个、也是唯一一个局部JAK抑制剂非节段型白癜风复色产品，有望成为中国获批上市的首款白癜风治疗药物，将填补市场空白，为中国白癜风患者带来新希望。此外，阿尔茨海默病新药ZUNVEYL的中国上市申请(NDA)亦已于今年7月获受理；消费医疗产品注射用聚左旋乳酸微球填充剂已获得上市批准，进一步丰富公司多元化产品矩阵。在研创新管线中，已有多款重磅候选药物进入中国后期临床开发阶段，预计将在未来1-3年内陆续进入商业化，形成持续放量的新动力。其中，合作产品注射用Y-3已完成中国III期临床，该产品为原创单分子1类新药，亦为全球唯一进入临床研究的非肽类PSD95/nNOS解偶联剂，并有望成为首个治疗缺血性卒中并预防卒中后抑郁焦虑的双功能脑细胞保护药物。另一个口服小分子1类新药ABP-671（URAT1抑制剂）用于治疗痛风及高尿酸血症，目前其中国IIb/III期临床正有序推进中。相较现有主流药物，该产品有潜力以更低剂量将尿酸降低至更低水平，并具有溶解痛风石的能力，有望为患者提供疗效更优、安全性更高的治疗选择。康哲药业亦持续增厚创新储备，不断夯实全链条创新实力，以实现创新产品分阶段、源源不断获批上市。2025上半年，公司新增ZUNVEYL、MG-K10（长效抗IL-4Rα人源化单抗注射液）两款合作开发创新产品。截至目前，公司累计布局约40款差异化创新管线，其中约20项为自主研发项目。同步推进"新模式"、"新地域"战略 拓展多维增量空间根据业绩公告，康哲药业持续推进"新模式-商业革新"战略，以多元生态锻造抗周期韧性；并坚定执行"新地域-国际拓展"战略，以产业国际化出海模式构建多维增长格局。在商业革新战略下，公司持续聚焦专科领域，同时拓展新零售、新媒体渠道，构建"院内+院外"、"线上+线下"全覆盖的营销推广体系，并持续强化消费医疗产品布局。公司皮肤健康业务"德镁医药"已在这一具消费属性的赛道崭露头角，自2021年独立运营以来，已实现皮肤疾病领域适应症覆盖广度、皮肤处方药收入规模的双重领先，将通过介绍上市、实物分派方式，拟分拆于香港联交所主板独立上市，进一步释放其独立价值与高成长潜力。国际化方面，2025年7月15日，公司以介绍方式成功于新加坡交易所完成第二上市，"产业国际化"战略迈入新里程。以新加坡为枢纽，公司构建起覆盖"研-产-销"的新兴市场全链条业务体系。截至目前，商业化平台公司Rxilient已在东南亚、中东、港澳台等地区累计提交近20款药品和器械注册申请，涵盖皮肤科、眼科、肿瘤、自免、中枢神经等领域。芦可替尼乳膏（白癜风适应症）已在澳门、香港获批，并已递交新加坡、台湾注册申请；静脉注射用特瑞普利单抗（首个被中国NMPA及美国FDA批准上市的国产抗PD-1单抗药物）已提交马来西亚等五国注册申请；替瑞奇珠单抗注射液、蔗糖羟基氧化铁咀嚼片亦在香港获批。同时，公司持股45.0%的联营CDMO生产工厂PharmaGend，目前已具备片剂、胶囊等口服固体制剂年产10亿片的能力，并获得新加坡HSA颁发的生产许可证、美国FDA cGMP认证及瑞士QP审计通过。PharmaGend鼻喷剂、乳膏、注射剂等新产线的建设正稳步推进中，为国际市场提供高标准生产交付能力。展望未来，"新康哲"增长逻辑有望加速兑现，盈利能力与业绩韧性将同步提升。公司正构建以差异化创新为核心、多元生态协同驱动、国际化布局支撑的增长体系，为高质量发展打开长期空间，为全球患者提供高品质医药产品和服务，为股东带来可持续回报。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，其中皮肤健康业务已成为该细分领域的龙头企业，带来专科规模效率。同时，康哲药业持续深化东南亚及中东区域业务发展，助力高质量持续健康发展。康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Global leading storage battery company in data center and telecom industries – Shuangdeng Group Co., Ltd. (stock code: 06960.HK), proposes to list its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).Shuangdeng Group plans to offer 58,557,000 H Shares (subject to the Over-allotment Option), of which 52,701,000 H Shares will be International Offer Shares (subject to reallocation and the Over-allotment Option), representing approximately 90% of the initial offer shares; the remaining 5,856,000 H Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial offer shares. The Offer Price is HK$14.51 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund).Shuangdeng Group will open for Hong Kong Public Offering in Hong Kong at 9 a.m., August 18, 2025 (Monday), and close at 12:00 noon, August 21, 2025 (Thursday). Dealings in H shares of Shuangdeng Group on the Main Board of the Hong Kong Stock Exchange is expected to commence on August 26, 2025 (Tuesday). The H shares will be traded in board lot of 500 H shares each. The Company’s stock code will be 06960.HK.China International Capital Corporation Hong Kong Securities Limited, Huatai Financial Holdings (Hong Kong) Limited and CCB International Capital Limited are Joint Sponsors, Sponsor-Overall Coordinators, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Mangers. Sanshui Venture Capital Co., Limited is the cornerstone investor, subscribing for H shares worthing approximately RMB220 million in total.Global leading storage battery company in data center and telecom industriesFounded in 2011 in Taizhou, Jiangsu Province in China, Shuangdeng Group is a leading company in energy storage business for big-data and telecommunication industries. With a deep understanding of the industry and customer demand, Shuangdeng Group has developed industry-leading technologies and multi-pathway products with optimal balance among safety, cost efficiency and performance, which enables it to capture huge growth potential in its industry. According to Frost & Sullivan, in 2024, the Company ranked the first among global telecom base station and data center energy storage battery providers in terms of shipment volume, achieving a market share of 11.1%.With its unwavering commitment to enhance the market recognition of its brand, Shuangdeng Group boast a high-quality global customer base with nearly 30 of the world’s top 100 telecom operators and equipment manufacturers, forging strong relationship with leading telecom operators and telecommunication equipment manufacturers in China, such as China Mobile, China Telecom, China Unicom, and China Tower, as well as prominent international telecommunication giants like Ericsson, Vodafone, Orange, and Telenor. In addition, as of December 31, 2024, Shuangdeng Group served 80% of top 10 Chinese self-owned data center companies and 90% of top 10 Chinese third-party data center companies.R&D capabilities in high safety, cost efficiency and superior performanceShuangdeng Group’s products span diverse application scenarios, including energy storage for telecom base stations, data centers, and the electrical energy storage settings. Shuangdeng Group continuously expand its technology portfolio to encompass lithium-ion batteries, lead-acid batteries, sodium-ion batteries, and solid-state batteries, ensuring it can provide the most suitable products for various application scenarios and diverse customer use. Its R&D efforts are focused on addressing the needs and pain points of customers operating telecom base stations and data centers, with a steadfast commitment to ongoing improvements in safety, cost, and performance of products.Shuangdeng Group has established a technical expert committee led by multiple academicians and comprised of over 30 renowned industry experts. This committee collaborates with distinguished experts from leading institutions such as China Electric Power Research Institute, Tsinghua University, Nanjing University, and Huazhong University of Science and Technology. Together, the Company has developed a long-term, stable research and communication mechanism, regularly engaging in academic exchanges to stay abreast of cutting-edge technological advancements. Through active collaboration between industry, academia, and research, Shuangdeng Group continuously optimizes its product manufacturing process and technologies, driving ongoing innovation. As of August 8, 2025, the Company held a total of 353 patents, including 111 invention patents.Data center business accelerates, emerging as a key growth driverWith the penetration and promotion of big data, technologies, energy storage batteries for data centers have become essential products for ensuring data security and energy security. In 2018, Shuangdeng Group keenly identified the market demands of the internet era and began establishing cooperation relationship with large tech companies and data center operators. Since 2018, the Company has successively collaborated with Alibaba, JD.com, Baidu, GDS, and ChinData. In 2022, Shuangdeng Group innovatively developed the first large-scale dual-function energy storage plan incorporating “backup power + power storage and management” for data centers in China, and supplied our products to the Xiong’an Urban Supercomputing Center, contributing its successful achievement of being recognized as national green data center. Up to August 8, 2025, its energy storage products have been used in hundreds of data centers.According to Frost & Sullivan, in 2024, Shuangdeng Group ranked first among Chinese companies in terms of shipment volumes in the global data center energy storage market and its market share in the global data center market reached 16.1%. Revenues from sales of batteries used in data centers increased by 120% YoY from RMB397.0 million in the five months ended May 31, 2024 to RMB872.9 million in the five months ended May 31. This expansion boosted its contribution to total revenue from 28.4% to 46.7%, making it the company’s largest revenue source. Driven by the increase in revenues from sales of batteries used in data centers, the Company’s total revenues increased from RMB1,394.2 million in the five months ended May 31, 2024 to RMB1,866.6 million in the five months ended May 31, 2025.An experienced and visionary management teamShuangdeng Group is led by a visionary, stable, and highly experienced management team. The Company’s Chairman, Dr. Yang Rui, brings extensive experience in the energy storage battery industry and a global perspective. He has been honored with multiple accolades, including the 2024 Person of the Year in Energy Storage Battery Industry, and Jiangsu Province Excellent Entrepreneur. His forward-thinking strategic decisions have driven the Company’s continuous innovation and growth. Its executive Director and deputy general manager, Dr. Yang Baofeng, is a senior engineer who has received distinguished honors, such as ‘‘Jiangsu Province Technology Entrepreneur’’ and ‘‘Innovation and Entrepreneurship Star.’’ He also serves as Vice Chairman of the China Battery Industry Association and the China Chemical and Physical Power Industry Association. Its senior management team possesses deep expertise in energy storage battery technology and business management. All senior team members have been with us for many years, ensuring effective management collaboration and a unified long-term business strategy.Dr. Yang Rui, Chairman of the Board, Executive Director and Chief Executive Officer of Shuangdeng Group said, “As a global leading storage battery company in data center and telecom industries, we always adhere to our customer-centric approach and devote ourselves to delivering the most suitable and premium batteries to our customers across various industries, including telecom operators and tech companies. As artificial intelligence technology ushers in a new era of widespread adoption, the surging demand for computing power will drive unprecedented growth in energy needs. In response to the expanding demand for computing power and the increasing energy consumption of data centers, we will maintain our innovative drive to seize growth opportunities in the data center sector and cultivate our second growth pillar. Meanwhile, we will continue to deepen our presence and penetration in existing markets while expanding our global presence, further strengthening our position as a globally leading brand.”Use of ProceedsShuangdeng Group estimates that it will receive net proceeds from the Global Offering of approximately HK$756.3 million, assuming the Over-Allotment Option is not exercised, after deducting the underwriting fees and commissions (assuming the full payment of the discretionary incentive fee) and estimated expenses payable by the Company. Approximately 40.0%, or approximately HK$302.6 million, will be used for the construction of a lithium-ion batteries production facility in Southeast Asia. Approximately 35.0% or approximately HK$264.7 million, is intended to be used to fund the establishment of a research and development center. Approximately 15.0%, or HK$113.4 million, is intended to be used to strengthen its overseas sales and marketing so that the Company can enhance its global presence, better serve its overseas customers and boost its international sales. And approximately 10%, or HK$75.6 million, will be used to provide funding for working capital and other general corporate purposes.For further information, please contact:Porda Havas International Finance Communications GroupMs. Kelly Fung+852 3150 6763kelly.fung@h-advisors.globalMs. May Yang+86 21 3397 8725may.yang@h-advisors.global Copyright 2025 ACN Newswire via SeaPRwire.com.

- The Food Expo, Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo, and Home Delights Expo successfully concluded today, bringing together approximately 1,890 exhibitors and welcoming over 500,000 visits.- The per capital spending across the five fairs reached HK$1,630.- 48% of respondents believe that health, green and organic food trends are worth paying attention to. Halal food and beverage label at the expo helps promote the development of halal foods.- The five theme days, along with a series of exciting activities effectively boosted local consumption and created a bustling atmosphere.- The International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM) featured 21 prominent speakers who shared innovative achievements and development trends in the globalisation of Chinese medicine.HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC), the Food Expo, Beauty & Wellness Expo, and Home Delights Expo successfully concluded today. Food Expo PRO and the Hong Kong International Tea Fair, which opened to both industry professionals and the public for the first time, wrapped up successfully on 16 August. The five exhibitions featured some 1,890 exhibitors and attracted over 500,000 visits. The bustling atmosphere resulted in a per capita spending of HK$1,630, once again demonstrating the appeal of this annual event and the public’s purchasing power. Over at Food Expo PRO and the Hong Kong International Tea Fair, there were some 18,500 buyers from 64 countries and regions. Apart from Hong Kong, buyers came from Mainland China, Japan, Korea, Taiwan, as well as ASEAN countries, including Cambodia, Malaysia, the Philippines, Thailand, and Vietnam, among others, highlighting Hong Kong's significant role as a key food trade hub globally. Additionally, the International Conference of the Modernization of Chinese Medicine and Health Products, organised by the Modernized Chinese Medicine International Association (MCMIA) together with the HKTDC and ten scientific research institutions, also concluded successfully on 15 August.Sophia Chong, HKTDC Deputy Executive Director, stated: "This year, the event featured five major themes across several exhibitions, complemented by a variety of exciting activities that encouraged people to spend locally. The atmosphere was vibrant, fully reflecting the public's enthusiasm for gourmet food and trendy products. Due to weather conditions on the first day, the opening hours of the public fairs from Friday to Sunday were extended to provide exhibitors with greater opportunities to maximise sales and enhance visitor experiences. The Hong Kong International Tea Fair, which opened to the public over all three days for the first time, attracted significant attention and praise.”Despite challenges from sluggish trade in traditional markets and geopolitical challenges, the HKTDC has consistently focused on driving innovation, helping small and medium-sized enterprises seize global development trends, and creating opportunities through innovative and flexible thinking.Ms Chong added: “At this year's Food Expo and Food Expo PRO, we specifically curated products and services related to halal food, the silver economy, and food technology to meet emerging market demands and capture more business opportunities for exhibitors. We are pleased to see that the five exhibitions successfully generated more business for exhibitors, and the public enjoyed the culinary and shopping experience fully."Per capita spending reached HK$1,630; increased interest in halal foodsDuring the exhibition, the organisers conducted a random sampling survey, interviewing some 1,440 visitors. The per capita spending reached HK$1,630. Over 58% of respondents reported spending HK$1,000 or more at the exhibition, and over 30% indicated that their actual spending exceeded their original budget, demonstrating a strong and thriving consumption atmosphere during the event. The survey results also showed respondents believe that health, green and organic food (48%), and nutritional supplements (36%) trends are worth paying attention to. Among the respondents who are aware that the exhibition has a halal food and beverage label, more than half of the respondents (52%) believe it helps promote the development of halal foods.Vibrant consumption at the exhibition: encouraging sales performanceAs a highly anticipated annual event in the city, the Food Expo is dedicated to highlighting exquisite delicacies and fine wines from around the world. Director of exhibitor Yick Cheong Ho (HK) Limited, Joan Chui, stated that the Flavours of Intangible Cultural Heritage theme day has drawn extra interest and expected revenue of approximately HK$900,000. Some exhibitors are further expanding their business through the Food Expo. Huaying Lei, the chairman of Mayang Blue Phoenix Agricultural Development Co., Ltd from Mainland China stated that the company had signed a RMB60 million contract with a Hong Kong client for agri-products including high-quality edible eggs. Lei believed the Food Expo offers a perfect platform to showcase their wide-ranging products from Hunan Province.The concurrently held Beauty & Wellness Expo offered visitors a diverse range of premium products, with brand Mars, a Taiwan whey protein brand, the brand marketing manager Roy Wong said, “This year, the visitor traffic exceeded our expectations and we expect our on-site sales will increase by 30% to HK$200,000.”The Home Delights Expo showcased a variety of trendy household items and furniture. Andy Tsang, the design director of Renovation Guide Consultant Limited - specialising in interior design and decoration and participating in the expo for the first time - said, “Such a large number of new customers visiting our booth went above and beyond our expectations. We provided quotations to over 20 new clients, and we estimate that sales turnover will be around HK$2-3 million."Trade exhibitions expand business networks; thriving opportunities in halal foodThe 3rd Food Expo PRO and the 35th Food Expo introduced halal food and beverage label last year to help exhibitors expand their market for halal products. This year, more than 120 food suppliers showcased halal products from around the world, a 20% increase compared to last year. Daniel Chan, Director of Hong Kong exhibitor, Koon Chun Hing Kee Soy & Sauce Factory Ltd., said the company had seen many buyers from different countries and regions and discussed cooperations with five Mainland China and local distributors and restaurants and also met a buyer from Indonesia through the Click2Match platform.The new "Coffee" zone also debuted this year, showcasing coffee products, accessories, and machines from various origins. Jin Lu, Operations Director of CSFA Holdings Shanghai Co. Ltd., stated that the company has engaged with nine exhibitors from Mainland China, the U.S., South Korea, and other regions. The company is interested in placing a coffee beans order of approximately 50 metric tons (worth around RMB3 million) from a Yunnan-based supplier, as well as a RMB700,000 order for premium hairtail fish from a Korea exhibitor.The highlight zone, "Food Science and Technology," brought alternative and future food to the attention of professional buyers. My Care Healthcare Limited, a manufacturer of modified soft diet products for the elderly. Founder Francis Ho said they had discussions with nearly 120 buyers on the first day. On the last day of the fair, HKTDC arranged specialised medical industry buyer tours of which there were two potential buyers and the company is in talks with two hospitals to discuss the potential of supplying soft meals to them.The Okinawa Prefectural Government Hong Kong Representative Office organised four Okinawan companies to participate in the Food Expo PRO and successfully connected with buyers from Hong Kong, Mainland China, and international markets. Director Yasutoshi Nohara stated the fair helps them generate around HK$4 million in orders every year. Mr Nohara said the expo has been instrumental in providing them with a great opportunity, particularly to introduce Okinawan products in the Greater Bay Area and expand beyond Hong Kong with items that have not been shown in other markets before, such as soft shell turtle and Motobu beef.Sichuan Sentaiyuan Biotechnology Co., Ltd. has participated in the Food Expo PRO for four consecutive years, promoting healthy products. The company’s CEO, Liu Lei shared, “On the first day of the Expo, we met a long-time Hong Kong client in person for the first time, leading to a successful deal worth over US$5 million. The HKTDC also introduced several potential buyers from Japan, Singapore, and other regions and we expect deals to be finalised soon.” Mr Lei also mentioned that through the hktdc.com Sourcing platform, the company received around 30 inquiries before the expo and arranged on-site meetings with several clients. The “EXHIBITION+” hybrid model has significantly boosted the company’s visibility and secure more business opportunities.The Hong Kong International Tea Fair opened to trade and public visitors on all three days for the first time. Yip Wing-chi, Founder of exhibitor, Lock Cha Tea House, welcomed this arrangement and noted that there was a significant increase in traffic, creating a lively atmosphere. The public participation has effectively boosted business. Mr Yip said this year's sales were three times higher than last year.Hybrid model connecting local and overseas opportunitiesThis year, both Food Expo PRO and the Hong Kong International Tea Fair continued to adopt the EXHIBITION+ hybrid model, enabling global food and tea buyers to engage in business discussions through both physical exhibitions and online platforms. Until 23 August, exhibitors and buyers can still utilise the "Click2Match" smart matching platform for online discussion and to explore business opportunities.Chinese Medicine Conference Gathers Experts and Scholars to Promote Industry ExchangeThe International Conference of the Modernization of Chinese Medicine and Health Products, organised by the Modernized Chinese Medicine International Association in partnership with the HKTDC and ten scientific research institutions, has successfully concluded. The conference unveiled the latest professional information on traditional Chinese medicine and shared innovative achievements and development trends in the globalisation of Chinese medicine. Held concurrently with the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO, and the Hong Kong International Tea Fair, the event covered diverse fields such as food, beauty, health, home products, and Chinese medicine, successfully creating a synergistic effect, providing a broad platform for industry exchange.Photo download: http://bit.ly/4mrgT4SThe Food Expo, Home Delights Expo, and Beauty & Wellness Expo, three public exhibitions organised by the Hong Kong Trade Development Council, along with the Food Expo PRO and the Hong Kong International Tea Fair, have successfully concluded, attracting over 500,000 visits to attend and shopThe Food Expo PRO featured multiple pavilions showcasing unique culinary delights from different countries and regions, with exhibitors displaying halal food and beverage label gaining increasing attentionThe Federation of Hong Kong Industries and the Incorporated Trustees of the Islamic Community Fund of Hong Kong launched the “Hong Kong Q-Mark Halal Scheme” at the Food Expo PRO, announcing their joint efforts to promote halal certification and its development, fostering the sustainable development of halal products and culture in Hong KongAt the Food Expo PRO, the HKTDC signed a Memorandum of Understanding with The Bank of Saga Ltd., to promote businesses in Saga, Fukuoka, and Nagasaki to further their development in Hong Kong and beyond, revitalising both the local economy and prosperity of the regionThe Hong Kong International Tea Fair opened to the public for the first time over its three-day exhibition period, drawing many visitors to explore a variety of tea beveragesThe five major theme days ran throughout the exhibition period, with the opening day (14 August) featuring "Shall We Tea'”, focusing on demonstrations of Northern and Southern dim sum and creative dim sum making, tea therapy workshops and other exciting activitiesOn 15 August, “Flavours of Intangible Cultural Heritage” featured hands-on experiences in making traditional Hakka “hand-pulled” noodles, as well as introductions to intangible cultural heritage steamer and bamboo craftmanship culture, along with steamer craft demonstrationsOn 17 August, “Body, Mind & Soul” responds to the business opportunities brought by the silver economy, with exhibitors launching a variety of products and services tailored for seniorsThe Beauty & Wellness Expo has introduced a new Polish pavilion this year, showcasing high-quality products such as caviar essence cream, pure natural essential oils, hair growth serums, and other products. The newly-established "Scentsation" zone focuses on perfumes and aromatherapy, featuring over 20 participating brandsThe Home Delights Expo's "Avenue of Delights" brand zone included more than 35 exhibitors, showcasing various lifestyle brandsThroughout the exhibitions, a series of highly popular and exciting events were held, including "Star Chef Cooking Demonstrations”, "Smart Bidding", and lucky drawsThe International Conference of the Modernization of Chinese Medicine and Health Products presented the latest professional information on Chinese medicine. The conference, themed "The Latest Research Progress in the Prevention and Treatment of Tumours, Inflammation and Cardiovascular and Cerebrovascular Diseases with Traditional Medicine", featured 21 prominent speakers, including experts from Hong Kong, mainland China, and overseas, sharing innovative achievements and development trends in the globalization of Chinese medicineTo learn more about the opinions of exhibitors and buyers, please visit:HKTDC Food Expo PROfoodexpopro.hktdc.comHong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM)icmcm.hktdc.com Media EnquiriesOgilvy Public Relations:Rex CheukTel:(852) 5618 9908email: rex.cheuk@ogilvy.comLeanne PokTel:(852) 9379 9694 email: leanne.pok@ogilvy.comDaisy LeungTel:(852) 9275 7704email: daisy.leung@ogilvy.comHKTDC’s Communications and Public Affairs Department:Stanley SoTel:(852) 2584 4049email: stanley.hp.so@hktdc.orgSerena CheungTel:(852) 2584 4272email: serena.hm.cheung@hktdc.orgClayton LauwTel:(852) 2584 4472email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

- Some 260 brands from 24 countries and regions set to participate, a new high for the event, with the UK debuting as Partner Country to present works by leading British designers- Internationally acclaimed couturier Guo Pei will stage her first solo couture show in Hong Kong, unveiling 30 meticulously crafted pieces under the theme “Gilternity: An Everlasting Radiance”- Aligning with market trends, the fair will introduce a new Accessories Zone and will once again feature the Circular Fashion Zone to promote the development of sustainable fashion- The Fashion Hong Kong Runway Show will celebrate the creative journey of local brands; around 30 fashion shows will be staged during the fair – the highest number in the event’s historyHONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC) and sponsored by the Cultural and Creative Industries Development Agency (CCIDA) of the Government of the Hong Kong Special Administrative Region (HKSAR), CENTRESTAGE – the annual gala event for the Asian fashion industry – takes place from 3 to 6 September 2025 at the Hong Kong Convention and Exhibition Centre (HKCEC). Unveiling a grand celebration of style for its 10th anniversary edition, this year’s CENTRESTAGE sees a record participation of some 260 brands from 24 countries and regions. The programme features more than 40 events, including around 30 fashion shows and parades – another record for the event. The four-day showcase is open to industry professionals and the public free of charge, welcoming visitors from Hong Kong, Mainland China and overseas to experience the charm and creativity of Asia’s fashion capital.Sophia Chong, Deputy Executive Director of the HKTDC, said: “Over the past decade, CENTRESTAGE has become the perfect meeting point for fashion brands and designers from across the globe, and Asia in particular, to showcase their latest creations. As the event celebrates its 10th anniversary, we are truly privileged to welcome internationally acclaimed couturier Guo Pei to present a collection at CENTRESTAGE ELITES, marking her first solo couture show in Hong Kong. As the flagship fashion event for Asia, CENTRESTAGE not only celebrates virtuosity in design and craftsmanship, but also propels both local and international brands into the broader Asian market, supporting the vigorous development of the local fashion industry and reinforcing Hong Kong’s status as a global fashion hub and world-class East-meets-West centre for cultural exchange.”This year’s CENTRESTAGE welcomes fashion brands from across the globe, including pavilions from the United Kingdom, Czech Republic, Japan and Thailand. The UK is participating for the first time as the "Partner Country" of CENTRESTAGE, showcasing unique creations from various British designers. Globally acclaimed fashion maestro Jimmy Choo will not only attend CENTRESTAGE in person but also spotlight his visionary initiative – the Jimmy Choo Academy – showcasing works by emerging designers nurtured by the Academy. The  Czechia pavilion will present personalised fashion labels that incorporate art-glass design; the Japan pavilion will spotlight emerging designers and brands, showcasing the creative force of Japan’s new generation; and the Thailand pavilion returns on an unprecedented scale, leading more than 40 brands to the show and expressing the rich diversity of Southeast Asian style. Brands from South Korea, Singapore and other countries will also exhibit their collections at the fair.CENTRESTAGE ELITES sees Guo Pei’s first solo couture show in Hong KongThe prestigious opening event, CENTRESTAGE ELITES, takes place on 1 September at M+ in the West Kowloon Cultural District, with internationally acclaimed couturier Guo Pei presenting her first solo couture show in Hong Kong. Guo Pei was the first Chinese designer invited to join the Fédération de la Haute Couture et de la Mode (FHCM) while also consecutively presenting 10 showcase collections in Paris. She previously participated in HKTDC Hong Kong Fashion Week for Fall/Winter in 2010, closing the Hong Kong Fashion Extravaganza with a spectacular finale.For CENTRESTAGE ELITES, Guo will present 30 one-of-a-kind couture creations under the theme "Gilternity: An Everlasting Radiance", drawing inspiration from the dazzling, fleeting moment of flowing molten gold. Fusing traditional craftsmanship with modern art, the collection epitomises her unparalleled artistry and technical mastery. In a gesture that honours both tradition and innovation, Guo has invited students from Hong Kong Polytechnic University (PolyU) to collaborate on the opening piece for the show.This grand occasion will be livestreamed on the CENTRESTAGE website and Instagram, the HKTDC’s YouTube channel, Facebook and official pages, and across multiple platforms including ViuTV Facebook and Yahoo HK. On the second day of the event (4 September), Guo Pei will appear in person for a master sharing session, offering rare in-person insights into her creative journey and design philosophy.Fashion Hong Kong Runway Show celebrates designers’ creative journeyOn the evening of 3 September, the Fashion Hong Kong Runway Show will take the stage under the theme "A Decade in Design: What is Seen' What is Felt'", exploring Hong Kong designers’ creative journeys. Four Hong Kong designer brands – ANGUS TSUI, ARTY:ACTIVE, IP AXIS INDUSTRIALSTUDIO and selfFab. – will showcase their innovative collections, merging visual impact and emotional narrative to spotlight the unique creativity of Hong Kong fashion design.Six thematic zones showcase sustainability and diversityCENTRESTAGE will be staged across six distinctive thematic zones, each offering its own unique appeal. The new Accessories Zone will present an array of fashion jewellery, handbags, footwear and other refined fashion accents, where style and function are seamlessly intertwined. The Athleisure Zone will champion activewear that unites aesthetics with practicality, reflecting the growing prominence of sports-inspired looks. The Craftsmanship Zone will showcase exquisite techniques and artisanal mastery that pay homage to heritage skills, while the Contemporary Zone will unveil forward‑thinking, avant‑garde creations from cutting‑edge designers. The Urban Zone will spotlight youth‑driven trends, including labels such as Petrolhead, helmed by artist Louis Cheung, which fuses motorcycle culture with a streetwear edge. Completing the lineup, the Circular Fashion Zone will advocate the possibilities presented by sustainable style, headlined by the 15th Redress Design Award Final at which the winning eco‑conscious collections will be showcased, promoting the industry’s focus on environmentally friendly design.The four-day fair will present a rich variety of happenings, including student showcases from PolyU’s School of Fashion and Textiles and the Hong Kong Design Institute, as well as an interdisciplinary exhibition from the Fashion Farm Foundation that combines music, art, product design and intangible cultural heritage, featuring traditional crafts such as gold-thread embroidery in bridal gowns and the making of Canton silk. A record-breaking total of 28 fashion shows will be held throughout CENTRESTAGE, featuring brands such as 112 mountainyam, CAMMIE CHAN CHEONGSAM, DorisKath, and KOWLOON CITY BOY that showcase the vibrant energy of the fashion industry.LOCAL POWER 2025, a cross-cultural project curated by Asian New Generation Creativity Design Association, will officially launch during CENTRESTAGE. This initiative will bring together designers from Hong Kong and Korea, presenting a thoughtfully curated exhibition and runway show that will help to foster cultural and creative exchanges between the two places. “THREAD OF CREATIVITY – Fashion Design Competition 2025" and Knitwear Innovation and Design Society Limited (KIDS) featuring the Young Knitwear Designers' Contest 2025 will also be held during the fair period.The HKTDC will continue to invite buyers from around the world to source at CENTRESTAGE, including major multi-brand stores such as WDLT 117 Apparel Inc. from Canada, Zalora from Indonesia, Sugar Srl from Italy and Hankyu Hanshin Department Stores from Japan.Spotlighting new talent at the YDCThe grand finale of CENTRESTAGE 2025 on Saturday, 6 September will be the Hong Kong Young Fashion Designers’ Contest (YDC), dedicated to discovering and nurturing new local talent. This year's competition will continue to promote a spirit of innovation and experimentation, allowing participants to fully showcase their creativity while injecting fresh talent into the industry. Charles Jeffrey, the designer behind the London label Charles Jeffrey LOVERBOY, has been invited as guest judge, joining a panel of other industry professionals to select winners from the 10 finalists vying for four major awards: Champion, Excellence Award, Best Art Direction and My Favourite Collection. Members of the public are invited to participate by casting votes online (https://bit.ly/YDC2025_IG_Vote_Now) for their favourite collection. Designer brands JESSE LEE and gnastiy.com, both former participants in the YDC, will showcase their new season special collections alongside guest performers at this year's YDC finale.CENTRESTAGE will be staged in parallel with the HKTDC Hong Kong Watch & Clock Fair and Salon de TIME, with visitors able to view the latest products from some 400 watch and fashion brands at the same venue. The fairs will also feature the CENTRESTAGE x Watch & Clock Lucky Draw. The brand-new CENTRESTAGE Instagram account (@centrestage_hktdc) is now officially live and will be updated with the latest event information and fashion trends. Everyone is welcome to follow and stay closely connected with all the latest happenings at CENTRESTAGE.Photo download: https://bit.ly/47uYUFOSharing highlights of this year’s CENTRESTAGE at today’s press conference are Sophia Chong, Deputy Executive Director of the HKTDC (second right); Katherine Fang, Chairman of the HKTDC Garment Advisory Committee (second left); Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (first right); and local fashion designer Angus Tsui (first left).The 2025 CENTRESTAGE exhibition will feature some 260 brands from 24 countries and regions – the largest brand lineup in the event’s history.The grand opening event, CENTRESTAGE ELITES, will be held on 1 September at M+ in the West Kowloon Cultural District. Internationally acclaimed couturier Guo Pei will present her first-ever couture show in Hong Kong. Her "Gilternity: An Everlasting Radiance" collection was previewed at today’s press conference.Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (left), and artist Marf Yau (right) wear creations from Patrick McDowell, a brand featuring at the UK Pavillion, at the CENTRESTAGE press conference.Local designer Angus Tsui (left) and artist/emcee Thor Lok (right) showcase a fashion piece designed by Angus Tsui.Websites- CENTRESTAGE: https://www.hktdc.com/event/centrestage/en- CENTRESTAGE ELITES: https://www.hktdc.com/event/centrestage/en/centrestage-elites- CENTRESTAGE Instagram: https://www.instagram.com/centrestage_hktdc/?hl=en- Fashion Hong Kong: https://www.fashionhongkong.com.hk/en- Hong Kong Young Fashion Designers' Contest (YDC): www.fashionally.com/enMedia enquiriesBest Crew Public Relations & MarketingDiana Tang Tel: (852) 9199 6723 Email: diana.tang@bestcrewpr.comReni Kwok Tel: (852) 6291 4283 Email: reni.kwok@bestcrewpr.comHKTDC Communication and Public Affairs Department:Sharon Ha Tel: (852) 2584 4575 Email: sharon.mt.ha@hktdc.orgKaty Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout the HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. About Cultural and Creative Industries Development Agency (CCIDA)The Cultural and Creative Industries Development Agency (CCIDA) established in June 2024, formerly known as Create Hong Kong (CreateHK), is a dedicated office set up by the Government of the Hong Kong Special Administrative Region (HKSAR Government) under the Culture, Sports and Tourism Bureau to provide one-stop services and support to the cultural and creative industries with a mission to foster a conducive environment in Hong Kong to facilitate the development of arts, culture and creative sectors as industries. Its strategic foci are nurturing talent and facilitating start-ups, exploring markets, promoting cross-sectoral and cross-genre collaboration, promoting the development of arts, culture and creative sectors as industries under the industry-oriented principle, and promoting Hong Kong as Asia’s creative capital and fostering a creative atmosphere in the community to implement Hong Kong’s positioning as the East-meets-West centre for international cultural exchange under the National 14th Five-Year Plan.CCIDA’s website: www.ccidahk.gov.hkDisclaimer: The Government of the Hong Kong Special Administrative Region provides funding support to the project only, and does not otherwise take part in the project. Any opinions, findings, conclusions or recommendations expressed in these materials/events (or by members of the project team) are those of the project organisers only and do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the CreateSmart Initiative Secretariat or the CreateSmart Initiative Vetting Committee. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月18日 - (亚太商讯 via SeaPRwire.com) - 2025 年8月17 日，全球首个以人形机器人为核心参赛主体的大型综合性赛事——世界人形机器人运动会，在北京国家速滑馆"冰丝带"圆满落幕。本届运动会由北京市人民政府、中央广播电视总台、世界机器人合作组织、亚太机器人世界杯国际理事会等单位联合主办，集聚全球 280 支战队、500 余台机器人同台竞技，展现了具身智能机器人从技术突破走向场景应用的完整产业链条。在本次大会中，首程控股（0697.HK）作为深度产业推动者，多家被投企业集体亮相，参与多个重点项目并获得优异成绩，共计斩获37枚奖牌，其中包括12金14银11铜（包括各战队使用被投企业本体机器人参赛获奖情况）。与此同时，首程控股还在"冰丝带"外场打造了面向公众开放的"首程机器人科技体验店"，成为大会期间最受关注的互动展区之一。一、多家被投企业集结亮相本次赛事首程控股本次参展的多家企业涵盖了人形机器人本体、底层技术平台、零部件能力与具身智能生态的多个核心环节：宇树科技：在 2025 世界人形机器人运动会圆满落幕之际，宇树科技以出色的表现获得了四金，再次证明了其在全球人形机器人领域的技术领先地位。宇树科技的机器人在多个项目中表现卓越，分别夺得1500米、400米、100米障碍赛和 4×100米接力赛的金牌，展现了其在速度、灵活性和稳定性方面的强大实力。此外，在本届赛事中，宇树科技的机器人最高速度达到了 4.78m/s，这一成绩距离其内部测试的 5+m/s 还有一定差距，未来在速度和灵活性方面仍有巨大的提升空间。基于宇树科技 G1 硬件平台开发的独立参赛队伍也取得了不俗成绩，分别获得了1金1银1铜，进一步验证了宇树科技平台的广泛适应性与强大性能。北京人形机器人创新中心：在2025世界人形机器人运动会上，北京人形机器人创新中心展现了卓越的技术实力和广泛的场景适应能力，累计斩获2金6银2铜，成为本届赛事最具代表性的"全自主执行"技术方之一。在竞技赛部分，其打造的"天工 Ultra"机器人是 1500 米比赛中唯一全程自主奔跑、无遥控介入的选手，最终获得银牌；在 100 米项目中夺得金牌，在 400 米项目中拿下银牌与铜牌各一枚，并在 4×100 米接力赛中获得银牌，全面展示了其在复杂运动控制、节奏协调与导航算法方面的领先优势。在场景赛中，创新中心自主研发的天轶 2.0 机器人，凭借慧思开物"具身大脑+具身小脑"的智能协同体系，在"物料整理"项目中包揽金银牌，在"物料搬运"项目中斩获银牌与铜牌，并在"酒店迎宾服务技能竞赛"中收获银牌。这些项目均要求高度精细化操作与复杂场景适应能力，充分体现了其在"自主感知-智能决策-精准执行"完整闭环中的技术突破。作为本届赛事中"全自主"能力最突出的参赛单位，北京人形机器人创新中心不仅实现了从实验室走向复杂实战场景的关键跨越，也为具身智能的落地提供了极具参考价值的技术路径。松延动力：在本次运动会自由体操项目中，由松延动力自主研发的人形机器人"小顽童"以出色的平衡性、动态控制与节奏感，夺得冠军，展现出融合 AI 与动态模仿控制的高水平舞台表现力；博远智行 1 队采用松延动力机器人参赛，也在同一项目中荣获季军。在跳远项目中，松延动力的机器人再次发挥出色，赢得了冠军，展示了其在运动精度与协调性方面的强大能力。在单机舞蹈项目中，松延动力联合北京舞蹈学院组建代表队参赛，凭借对细节动作的精准复现和对舞台艺术的深度理解，最终斩获亚军，成为本届赛事"科技×艺术"融合的典范之一。松延动力此次在体操、跳远和舞蹈三个项目中斩获二金一银一铜，不仅证明了其机器人平台在高动态控制与 AI 动作生成领域的前沿实力，也进一步拓宽了人形机器人在文教娱乐、公共服务等方向的实际应用边界。银河通用：在首届世界人形机器人运动会中，银河通用 Galbot 队凭借全自主操作勇夺分拣技能竞技冠军。同时，来自中国矿业大学的北京北矿梦之队和北京建筑大学队等多支高校队伍也选择银河通用机器人参赛，均成功闯入复赛，其中矿大与北建大更是闯入决赛，最终分获亚军与第四名。至此，冠亚军由银河通用及采用银河通用机器人的队伍共同包揽，充分展现了银河通用技术的行业引领性与产品的通用性。星海图：在本次运动会中，星海图深度参与赛事生态构建，作为场景赛独家整机提供商，提前三周入驻实训场，为来自全国的 20 余支顶尖团队（包括北京林业大学、清华大学、北京航空航天大学等）提供总计 8 台人形机器人 R1 Pro、通用双臂移动操作平台 R1 Lite 及配套 VR 设备，并搭建开放软硬件平台，支撑参赛团队将创新算法从仿真环境部署至真实场景。场景赛覆盖的场景包括，酒店服务（床铺整理、迎宾行李搬运）、仓储中心（混合物料分拣）、医院场景（药品识别与补货）及工业场景（异物分拣与物料搬运）。走进冰丝带，就能看到星海图机器人和参赛选手们忙碌的身影。本次比赛中，来自北京航空航天大学的代表队采用星海图本体参与拆药分装场景赛，并成功获得季军，充分验证了星海图为开发者提供的具身智能开发平台的能力。加速进化：作为足球项目的核心技术支持方，加速进化为 3V3、5V5 等全部足球项目提供了竞技型人形机器人，承担了赛事中全部参赛队伍的机器人硬件支持与赛中技术保障。提供的机器人以高动态控制能力、抗干扰能力和场景适应性著称，展现了良好的对抗与战术执行能力。虽不作为直接参赛队伍名义参赛，但加速进化提供的技术平台承载了赛事中全部足球类奖牌的实现，是足球项目"幕后冠军"。二、科技体验走进生活，打造机器人产业"样板间"大会期间，首程控股在场馆外开设的"首程机器人科技体验店"也成为市民与游客热烈打卡的科技热点。店内集中展出200余款智能产品，涵盖智慧家居、儿童教育、AI娱乐、智能穿戴、户外运动等多个生活化场景。体验区共分为生态企业展示区、儿童互动区、医疗辅助区、AI音乐互动区等多个版块，成为让机器人"看得见、摸得着、用得上"的现实样本。首程控股执委、联席总裁叶芊在接受采访时表示："我们希望通过这次展示，让大家感受到机器人离生活越来越近。场馆内比的是专业能力，我们的体验店则通过贴近真实场景的互动设计，拉近机器人与大众的距离。"体验店内各展区的亮点纷呈：生态展示区以松延动力为代表，展示具备表情识别、人脸互动能力的拟人机器人，体现大模型与形态融合的前沿趋势；儿童体验区配置了汤姆猫、国际象棋机器人、AI 陪伴机器人和扫地机器人等设备，是全店人气最高区域；外骨骼与康复区设置跑步机、自行车等模拟设备，观众可实地体验机器人助力运动；智能穿戴区引入光粒品牌游泳眼镜，具备实时导航和运动数据采集能力；人机互动区展示了机器人自主演奏乐器及 AI 打击乐器、智能电吉他产品，深受观众欢迎；同时展出的还有 AI 中医问诊设备、具身底盘平台、机械臂抓取系统等，体现了机器人从"有脑、有脚、有手"的系统能力整合。三、首家正式体验店即将开业，全国推广启动在即本次"首程机器人科技体验店"为快闪形式试运营，但已获得极大市场关注。正式体验店预计将于"十一"期间在北京石景山-融石广场开业，后续还将布局至全国多个城市与重点场景（机场、高校、商圈等），形成连锁化、场景化的销售与体验网络。叶芊表示："我们将其定位为面向 C 端用户与城市生活空间的机器人应用窗口，也希望通过这类门店，持续验证市场需求、推动产品优化，帮助更多机器人企业走向商业化落地。"四、每一块奖牌，都是机器人走向未来的一小步人形机器人产业正在迎来从实验室走向真实场景的拐点。正如首程控股董事会办公室总经理康雨所指出："这场运动会，不仅比拼技术的高度，更关乎产业的温度--是一次让机器人真正走向应用、走进生活的生动演练。"未来，首程控股将持续依托"股权投资+资产运营"双轮驱动战略，携手被投企业与行业伙伴，推动机器人从看得见、摸得着的技术突破，走向用得上、可推广的现实应用，在教育、制造、城市运营、医疗康养等核心领域释放"下一代生产力"的真正价值。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亚太商讯 via SeaPRwire.com.

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - On August 17, 2025, the inaugural World Humanoid Robot Games—an international event centered on humanoid robots—concluded successfully at the National Speed Skating Oval in Beijing, also known as the “Ice Ribbon.”Co-hosted by the Beijing Municipal Government, China Media Group, the World Robot Cooperation Organization, and the Asia-Pacific RoboCup Council, the Games gathered 280 teams and over 500 robots from around the globe to compete across 26 disciplines, showcasing the full industrial chain from technological breakthroughs to real-world applications in embodied intelligence.As a key industrial accelerator, Shoucheng Holdings (0697.HK) saw several of its portfolio companies participate in major events, collectively winning 37 medals (12 gold, 14 silver, and 11 bronze), including awards where teams utilized robots built by Shoucheng’s portfolio firms. Simultaneously, Shoucheng launched the "Shoucheng Robot Tech Experience Store" adjacent to the venue, which became one of the most visited tech exhibits of the event.Highlights from Portfolio Companies:Unitree Robotics captured 4 gold medals and achieved a top speed of 4.78 m/s; G1-based teams earned an additional 1 gold, 1 silver, and 1 bronze;Beijing Humanoid Robot Innovation Center won 2 gold, 6 silver, and 2 bronze, representing the most advanced “fully autonomous execution” capabilities;Noetix Robotics earned 2 gold, 1 silver, and 1 bronze in gymnastics, long jump, and dance events, becoming a standout in “Tech × Art” integration;Galbot (by Galbot Technologies) secured the autonomous sorting championship and supported university teams that swept the podium;Galaxea-AI served as exclusive hardware provider in scene-based competitions and enabled a third-place finish by Beihang University;Booster Robotics powered all 3V3 and 5V5 football events, providing robot hardware and technical support, and was deemed the “backstage champion.”Robot Tech Experience Store: Bringing Innovation to the EverydayDuring the event, Shoucheng launched a pop-up “Robot Tech Experience Store,” featuring over 200 smart products across home, education, entertainment, healthcare, and wearables. The official store will open during China’s National Day Golden Week in October 2025 at Fusion Stone Plaza, Beijing, with nationwide expansion plans into airports, campuses, and commercial hubs.As Shoucheng’s Executive Director and Co-President Ye Qian stated: “Through interactive and relatable scenarios, we want the public to feel that robots are no longer distant technologies—they’re becoming part of daily life.”From Lab to Market: Accelerating the New Productive ForceWith a dual strategy of equity investment and asset operations, Shoucheng Holdings will continue to drive commercialization of humanoid and embodied robots in education, manufacturing, healthcare, and smart city operations, unlocking the full potential of the next-generation productivity paradigm.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

重点成果- 期内，集团共有2个创新产品获中国国家药品监督管理局（「NMPA」）批准上市，分别为普坦宁（美洛昔康注射液(II)）和安启新（注射用重组人凝血因子VIIa N01）。- 2025年上半年，集团创新产品收入达到人民币78亿元，同比增长27.2%。除创新产品外，集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持正增长。- 截至2025年6月30日，集团共有37个肿瘤领域、7个肝病╱代谢领域、13个呼吸系统领域、和6个外科╱镇痛领域的创新候选药物处于临床申请及以上开发阶段。其中，2个肿瘤领域、1个外科╱镇痛领域产品处在上市申请阶段；11个肿瘤领域、1个肝病╱代谢领域、3个呼吸系统领域、1个外科╱镇痛领域的创新候选药物处于临床III期；另有13个肿瘤领域、6个肝病╱代谢领域、12个呼吸系统领域、6个外科╱镇痛领域的生物类似药或仿制药候选药物处于临床申请及以上开发阶段。- 福可维（盐酸安罗替尼胶囊）是一种新型小分子多靶点酪氨酸激酶抑制剂，目前已获批9个适应症，另有3个适应症处于上市申请阶段。此外，安罗替尼还有多项新适应症处于III期临床研究阶段，包括一线非鳞状非小细胞肺癌、一线胰腺癌等，预计将在未来两年逐步递交上市申请。- 2023-2024年，集团共有5款肿瘤领域的国家1类创新药获批上市，分别为：亿立舒（艾贝格司亭α注射液）、安得卫（贝莫苏拜单抗注射液）、安柏尼（富马酸安奈克替尼胶囊）、安洛晴（枸橼酸依奉阿克胶囊）和安方宁（格索雷塞片）；以及4款肿瘤领域的生物类似药获批上市，分别为：安倍斯（贝伐珠单抗注射液）、得利妥（利妥昔单抗注射液）、赛妥（注射用曲妥珠单抗）和帕乐坦（帕妥珠单抗注射液）。该等产品在2025年上半年快速放量，成为集团收入增长的重要贡献品种。- 拉尼兰诺（泛PPAR激动剂）是一种口服小分子药物，用于治疗代谢功能障碍相关脂肪性肝炎（MASH），目前正在全球开展III期临床试验，已完成全部受试者入组。2023年7月，拉尼兰诺被药品评审中心「CDE」纳入突破性治疗药物程序。拉尼兰诺是中国第一个进入临床III期的MASH口服药物，有望填补中国市场空白。- 天晴速畅（吸入用布地奈德混悬液）是中国首款获批上市的布地奈德雾化剂型仿制药，打破了国内市场长期被原研垄断的局面，为国内气道慢性炎症患者带来了兼具有效性、安全性与经济性的高端制剂产品。该产品已被纳入集采范围，集团及时采取了一系列主动管理措施，包括管道下沉、拓展市场覆盖和集采外市场的二次开发。- 泽普思╱得百安（氟比洛芬凝胶贴膏）是中国首个获批上市的国产凝胶贴膏，连续多年蝉联外用镇痛市场份额第一位。集团聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求，推动泽普思/得百安销售额持续快速增长。集团开发的第二代氟比洛芬贴剂预计将在一年内获批上市。通过剂型升级，二代产品可显著提高药物透皮吸收度，增强贴膏粘附性，从而提升患者的依从性。香港，2025年8月18日 - (亚太商讯 via SeaPRwire.com) - 中国领先的创新研发驱动型医药集团-中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2025年6月30日止6个月（「期内」）之未经审核财务业绩。回顾期内，集团收入同比增长10.7%至约175.7亿元（人民币，下同）。来自持续经营业务之归属于母公司持有者应占盈利财务报表所示约33.9亿元，同比增长约140.2%，基于归属于母公司持有者应占盈利计算之每股盈利约18.82分。归属于母公司持有者盈利同比显著增长主要受惠于本期间收入明显增长及股息收益和投资公允价值变动收益明显增长。归属于母公司持有者之基本溢利（非香港财务报告准则指标）约30.9亿元，同比增长约101.1%。集团流动资金保持充裕，期内有计入流动资产之现金及银行结余约111亿元、计入非流动资产之银行存款约101亿元，理财管理产品总额约92.9亿元，资金储备合共约304.9亿元。董事会建议派发中期股息每股5港仙（2024上半年：3港仙）。销售：研发创新动能强劲，多领域销售成果持续放量集团一直以来重视研发，持续加大投入以提升研发质效，研发实力显著增强，驱动销售收入持续增长，成果丰硕。期内，抗肿瘤用药之收入同比增加24.9%，达约66.9亿元，占集团收入约38.1%。外科／镇痛用药之收入同比增加20.2%，达约31.1亿元，占集团收入约17.7%。肿瘤领域，集团全面布局非小细胞肺癌领域，覆盖多种分型的全线治疗，EGFR/cMet双抗TQB2922即将启动二线非小细胞肺癌III期临床，EGFR/cMet双抗ADC TQB6411 I期临床正在入组，两款产品进度均位于中国前列；深度布局乳腺癌三大亚型， CDK2/4/6抑制剂库莫西利胶囊有望成为HR+/HER2-乳腺癌的BIC疗法，HER2双抗ADC TQB2102较DS-8201潜在安全性优效，多个适应症正在同步拓展，其中三项乳腺癌III期快速推进；系统布局消化道领域结直肠癌、胃癌、胰腺癌、肝癌等核心癌肿，LM-108(CCR8单抗)、TQB2868(PD-1/TGF-β双功能融合蛋白)研发进度全球最快，且目前临床数据展示出了极大潜力。于外科╱镇痛领域，集团持续聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求。期内，集团推动泽普思销售额持续快速增长，而开发的第二代氟比洛芬贴剂预计将在一年内获批上市。同时，2025年5月获批的普坦宁凭借长效镇痛、安全性优异等优势，有望成为该领域新的增长动力。研发：全力以赴推动创新产品开发，加大研发的资金投入于报告期内，集团共有2个创新产品获NMPA批准上市，分别为普坦宁（美洛昔康注射液(II)）和安启新（注射用重组人凝血因数VIIa N01）。2025年上半年，集团创新产品收入达到人民币78亿元，同比增长27.2%。除创新产品外，集团还有5个仿制药获NMPA批准上市，整体仿制药收入在2025年上半年保持正增长。一直以来，集团十分重视研发，不断提升研发水平和速度，并视其为可持续发展的基础，加大研发的资金投入。截至二零二五年六月三十日止六个月，研究与开发成本约人民币318,756万元，占本集团收入约18.1%，连同已资本化的研发总开支出在内，约95.7%已计入损益表中。展望：深化创新与国际化布局，加速构建全球医药创新竞争力当前，中国医药产业正迎来历史性发展机遇。在国家创新驱动发展战略的指引下，我国生物医药创新能力显著提升，创新药研发已从「跟跑」逐步迈向「并跑」甚至「领跑」阶段。中国创新药不仅在本土市场构建起强劲的增长势能，更在全球市场逐步崭露头角，日益获得广泛认可，已成为全球医药创新产业中不可替代的重要力量。作为行业领军企业，集团深耕肿瘤、肝病╱代谢、呼吸系统及外科╱镇痛四大核心治疗领域，专注创新，服务病患，目标成为全球领先的制药企业。集团深耕中国市场，同时将战略视野投向全球市场，以国际化加速创新发展。同时，集团大力推进全球战略合作布局，通过商务拓展（BD）、战略收购等多元合作路径，快速充实创新管线储备，强化核心技术平台。2025年7月，集团宣布全资收购礼新医药。礼新医药拥有全球领先的抗体发现和ADC技术平台，包括肿瘤微环境特异性抗体开发平台 (LM-TME™)、针对难成药靶点的抗体开发平台（LM-Abs™），新一代抗体偶联药物平台（LM-ADC™）、以及免疫细胞衔接器平台（LM-TCE™）。此次收购将进一步增强集团的创新研发能力，加速集团的创新业务增长。此外，礼新医药卓越高效的研发团队将加入集团，进一步强化集团的创新研发人才储备，为持续产出高水平创新成果提供保障，助力创新生态的长远发展。未来，本集团将继续聚焦创新，提升四大治疗领域的研发效率与质量，加快国际化步伐，力争实现业务快速发展与业绩稳步提升。有关中国生物制药有限公司（股票编号：1177）中国生物制药，连同其附属公司，是中国领先的创新研究和研发驱动型医药集团，业务覆盖医药研发平台、智慧化生产和强大销售体系全产业链。产品包括多种生物药和化学药，在肿瘤、肝病/代谢、呼吸系统、外科/镇痛四大治疗领域处于优势地位。公司于2000年在香港联交所上市，2013年入选MSCI全球标准指数之中国指数成分股；2018年入选恒生指数成分股；2020年入选恒生沪深港通生物科技50指数成分股、恒生中国(香港上市)25指数。中国生物制药连续七年荣登美国权威杂志《制药经理人》发布的「全球制药企业TOP50」，连续三年获评《福布斯》(亚洲) 「亚太最佳公司50强」。有关中国生物制药的进一步资料，请浏览: www.sinobiopharm.com Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com